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2ABSTRACT
Isoflavones are polyphenols which are found in the plant kingdom, mainly in legumes.
The interest towards isoflavones has grown during the years, mainly because of their
reported beneficial health effects. Isoflavones exist in plants as their glycosides and are
readily hydrolysed in mammals to their free forms, mainly daidzein, genistein and
glycitein. These hydrolysed isoflavones are further metabolised to more water soluble
compounds, like sulphates, glucuronides and sulphoglucuronides which are then excreted
from the body in urine or feces. To understand and reveal the absolute metabolic route of
isoflavones, and further study their biological activity, model compounds of these
naturally occurring metabolites are needed.
During this study different approaches were studied to obtain isoflavone sulphates,
glucuronides and sulphoglucuronides. Three isoflavone disulphates (daidzein-di-O-
sulphate, genistein-di-O-sulphate and glycitein-di-O-sulphate) and three isoflavonoid
disulphates (dihydrodaidzein-di-O-sulphate, dihydrogenistein-di-O-sulphate and equol-di-
O-sulphate) were synthesised in moderate yields by using in situ prepared pyridine
sulphur trioxide complex, made from chlorosulphonic acid and pyridine. These
disulphated compounds can be used to develop analytical procedures and study the
biological activity of disulphated products.
As the use of the HPLC-MS methods in the field of isoflavones has increased its
popularity, deuterated isoflavone disulphates were synthesised. A new microwave assisted
deuteration method, using CF3COOD, was developed for this purpose. Three
polydeuterated isoflavone disulphates (daidzein-d6-di-O-sulphate, genistein-d4-di-O-
sulphate and glycitein-d6-di-O-sulphate) were obtained in moderate yields with high
isotopic purity.
A synthetic method was developed for daidzein sulphoglucuronide (daidzein-7-O-b-D-
glucuronide-4´-O-sulphate), which is a major metabolite in rat bile. By using
protection/deprotection steps, the desired product was finally obtained in moderate yield.
The method developed can be used in further studies of synthesis of isoflavonoid mixed
conjugates. As a part of this study, the structure of naturally occurring daidzein-4´-O-b-
glucoside was verified. Different glycosidation methods are reviewed and possible factors
affecting the stereoselectivity are discussed.
The study of the selective chlorination of isoflavones was a consequence of the observed
unexpected chlorination during the synthesis of isoflavone acid chlorides by thionyl
chloride. This fascinating phenomenon was investigated further with various isoflavones
and as a result a method for producing isoflavone chlorides (8-chlorogenistein, 6,8-
dichlorogenistein and 6,8-dichlorobiochanin A) was developed.
Protecting groups played a great role during this study, which led to an intensive study on
them. A regioselective protection method was developed by using direct introduction of
the protecting group (Benzyl and Benzoyl) to positions 7-O or 4´-O in daidzein, genistein
and glycitein with t-BuOK as a base in DMF in moderate yields. The possibility of
exploiting the transesterification was also investigated. It was observed that by using
K2CO3 as a base in DMF, daidzein, genistein and glycitein could be benzoylated at
position 4´-O selectively, in the presence of the more acidic 7 hydroxy group.
3Transesterification also proved to be useful in the glycosidation of isoflavones at position
7-O, starting from 7-O-benzoylated isoflavones.
Different carboxylic acid derivatives were synthesised for use either in the development of
radioimmunoassay (7-O-carboxymethylglycitein and 4´-O-carboxymethylglycitein) or
synthesis of daunorubicin isoflavone derivative for biological testing (7-O-
carboxypropylbiochanin A and 7-O-carboxypropylgenistein).
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8APPREVIATIONS
Ac Acetyl
Ac2O Acetic acid anhydride
AcOH Acetic acid
aq. Aqueous
BF3-Et2O-Me2S Boron trifluoride diethyl ether dimethyl sulphide
Bn Benzyl
BnCl Benzyl chloride
n-BuLi n-Butyl lithium
Bz Benzoyl
BzCl Benzoyl chloride
Bu4NBr Tetrabutylammonium bromide
t-BuOCl tert-Butyl hypochlorite
t-BuOH tert-Butanol
t-BuOK Potassium tert-butoxide
CN Nitrile
CpZrCl2-AgBF4 Bis-cyclopentadienylzirconium dichloride silver tetrafluoroborate
DCC N, N´-dicyclohexylcarbodiimide
DMF Dimethyl formamide
DMSO Dimethyl sulphoxide
DTMAB Dodecyltrimethylammonium bromide
GC Gas chromatography
GC-MS Gas chromatography - mass spectrometry
EI Electron impact
ESI Electrospray
Et3N Triethylamine
Et2O Diethyl ether
EtOAc Ethyl acetate
EtOH Ethanol
eq. Equivalent
HC(OEt)3 Triethyl orthoformate
HCO2Et Ethyl formate
HMBC (1H-13C) Heteronuclear multiple bond correlation (proton-carbon)
HPLC High pressure liquid chromatography
HPLC-MS High pressure liquid chromatography - mass spectrometry
HMQC (1H-13C) Heteronuclear multiple quantum correlation (proton-carbon)
IR Infrared
MDR Multi drug resistance
MeNH2 Methyl amine
MeOH Methanol
Me3SiI Trimethylsilyl iodide
MeSO2Cl Methanesulphonyl chloride
MPLC Medium pressure liquid chromatography
MS Mass spectrometry / Molecular sieve
MW Microwave
N2H4-H2O Hydrazine hydrate
NMP N-Methyl-2-pyrrolidone
NMR Nuclear Magnetic Resonance
Pd/C Palladium on charcoal
9Pd(OH)2/C Palladium hydroxide on charcoal (Pearlman’s catalyst)
Pd(PPh3)4 Tetrakis(triphenylphosphine)palladium(0)
PhSH Thiophenol
pKa Negative logarithm of the acid ionization constant
psi Pound per square inch
RP Reverse phase
RT Room temperature
SN1 Unimolecular nucleophilic substitution
SN2 Bimolecular nucleophilic substitution
SO3-Me3N Sulfurtrioxide trimethylamine complex
SO3-DMF Sulphur trioxide dimethyl formamide complex
SO3-pyridine Sulphur trioxide pyridine complex
TBAHS Tetrabutyl ammonium hydrogen sulphate
TBDMS t-Butyldimethylsilyl moiety
TCE 2,2,2-Trichloroethyl
TEMPO Tetramethylpiperidine nitroxyl
TFA Trifluoroacetic acid
THF Tetrahydrofuran
TLC Thin layer chromatography
TMS Tetramethylsilane
TMSOTf Trimethylsilyl trifluoromethanesulphonate
TR-FIA Time resolved fluorescent immunoassay
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STRUCTURES OF THE MONOSACCHARIDES
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OAc
AcO OAc
AcO
OAc
Penta-O-acetyl-b-D-glucopyranose (59)
O
F
OAc
AcO
AcO
OAc
Tetra-O-acetyl-1-fluoro-a-D-glucopyranosyl (61)
O
AcO OAc
AcO
OAc
Tetra-O-acetyl-1-bromo-a-D-glucopyranosyl (62)
Br
O
Br
OAc
AcO
AcO
H3C
Tri-O-acetyl-1-bromo-a-L-quinovopyranosyl (64)
O
Br
OAc
AcO
AcO
O
O
Tri-O-acetyl-1-bromo-a-D-glucopyranuronic acid
methyl ester (70)
O Br
BzO OBz
BzO
Tri-O-benzoyl-1-bromoa-D-arabinofuranosyl (73)
O
OAcAcO
OAcAcO
Tetra-O-acetyl-b-D-ribofuranose (81)
O
FAcO
H3C
OAcAcO
Tri-O-acetyl-1-fluoro-a-L-rhamnopyranosyl (83)
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LIST OF COMPOUNDS AND THEIR IUPAC SYSTEMATIC NAMES IN ORDER OF
APPEARANCE
daidzin (1)
3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl b-D-glucopyranoside
genistin (2)
5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl b-D-glucopyranoside
glycitin (3)
3-(4-hydroxyphenyl)-6-methoxy-4-oxo-4H-chromen-7-yl b-D-glucopyranoside
daidzein (4)
7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one
genistein (5)
5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one
glycitein (6)
7-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-4H-chromen-4-one
estradiol-17b (7)
estra-1,3,5(10)-triene-3,17b-diol
daidzein-7-O-glucuronide (8)
3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl-b-D-glucopyranosiduronic acid
genistein-7-O-glucuronide (9)
5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl-b-D-glucopyranosiduronic acid
glycitein-7-O-glucuronide (10)
3-(4-hydroxyphenyl)-6-methoxy-4-oxo-4H-chromen-7-yl-b-D-glucopyranosiduronic acid
daidzein-7-O-sulphate (11)
3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl hydrogen sulphate
daidzein-4´-O-glucuronide (12)
4-(7-hydroxy-4-oxo-4H-chromen-3-yl)phenyl b-D-glucopyranosiduronic acid
genistein-4´-O-glucuronide (13)
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4-(5,7-dihydroxy-4-oxo-4H-chromen-3-yl)phenyl b-D-glucopyranosiduronic acid
daidzein-4´-O-sulphate (14)
4-(7-hydroxy-4-oxo-4H-chromen-3-yl)phenyl hydrogen sulphate
genistein-4´-O-sulphate (15)
4-(5,7-dihydroxy-4-oxo-4H-chromen-3-yl)phenyl hydrogen sulphate
daidzein-7-O-glucuronide-4´-O-sulphate (16)
4-oxo-3-[4-(sulphooxy)phenyl]-4H-chromen-7-yl-b-D-glucopyranosiduronic acid
genistein-7-O-glucuronide-4´-O-sulphate (17)
5-hydroxy-4-oxo-3-[4-(sulphooxy)phenyl]-4H-chromen-7-yl b-D-glucopyranosiduronic
acid
daidzein-7,4´-di-O-sulphate (18)
4-[4-oxo-7-(sulphooxy)-4H-chromen-3-yl]phenyl hydrogen sulphate
equol (19)
3-(4-hydroxyphenyl)chroman-7-ol
dihydrodaidzein (20)
7-hydroxy-3-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one
dihydrogenistein (21)
5,7-dihydroxy-3-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one
3´-hydroxydaidzein (22)
3-(3,4-dihydroxyphenyl)-7-hydroxy -4H-chromen-4-one
O-demethylangolensin (23)
1-(2,4-dihydroxyphenyl)-2-(4-hydroxyphenyl)propan-1-one
dihydrodaidzein-7-O-glucuronide (24)
3-(4-hydroxyphenyl)-4-oxo-3,4-dihydro-2H-chromen-7-yl b-D-glucopyranosiduronic acid
O-desmethylangolensin-7-O-glucuronide (25)
3-hydroxy-4-[2-(4-hydroxyphenyl)propanoyl]phenyl b-D-glucopyranosiduronic acid
genistein-7-O-sulphate (26)
5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl hydrogen sulphate
genistein-7,4´-di-O-sulphate (27)
4-[5-hydroxy-4-oxo-7-(sulphooxy)-4H-chromen-3-yl]phenyl hydrogen sulphate
equol-7-O-sulphate (28)
3-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-7-yl hydrogen sulphate
equol-4´-O-sulphate (29)
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4-(7-hydroxy-3,4-dihydro-2H-chromen-3-yl)phenyl hydrogen sulphate
O-desmethylangolensin-7-O-sulphate (30)
3-hydroxy-4-[2-(4-hydroxyphenyl)propanoyl]phenyl hydrogen sulphate
O-desmethylangolensin-4´-O-sulphate (31)
4-[2-(2,4-dihydroxyphenyl)-1-methyl-2-oxoethyl]phenyl hydrogen sulphate
equol-7, 4´-di-O-sulphate (32)
4-[7-(sulphooxy)-3,4-dihydro-2H-chromen-3-yl]phenyl hydrogen sulphate
O-desmethylangolensin-7,4´-di-O-sulphate (33)
4-{2-[2-hydroxy-4-(sulphooxy)phenyl]-1-methyl-2-oxoethyl}phenyl hydrogen sulphate
equol-7-O-glucuronide (34)
3-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-7-yl b-D-glucopyranosiduronic acid
equol-4´-O-glucuronide (35)
4-(7-hydroxy-3,4-dihydro-2H-chromen-3-yl)phenyl b-D-glucopyranosiduronic acid
O-desmethylangolensin-4´-O-glucuronide (36)
4-[2-(2,4-dihydroxyphenyl)-1-methyl-2-oxoethyl]phenyl b-D-glucopyranosiduronic acid
daidzein-7,4´-di-O-glucuronide (37)
4-[7-(b-D-glucopyranuronosyloxy)-4-oxo-4H-chromen-3-yl]phenyl b-D-
glucopyranosiduronic acid
genistein-7,4´-di-O-glucuronide (38)
4-[7-(b-D-glucopyranuronosyloxy)-5-hydroxy-4-oxo-4H-chromen-3-yl]phenyl b-D-
glucopyranosiduronic acid
O-desmethylangolensin-7,4´-di-O-glucuronide (39)
4-{2-[4-(b-D-glucopyranuronosyloxy)-2-hydroxyphenyl]-1-methyl-2-oxoethyl}phenyl b-
D-glucopyranosiduronic acid
equol-7-O-glucuronide-4´-O-sulphate (40)
3-[4-(sulphooxy)phenyl]-3,4-dihydro-2H-chromen-7-yl b-D-glucopyranosiduronic acid
O-desmethylangolensin-7-O-glucuronide-4´-O-sulphate (41)
3-hydroxy-4-{2-[4-(sulphooxy)phenyl]propanoyl}phenyl b-D-glucopyranosiduronic acid
2, 4-dihydroxydeoxybenzoin (42)
1-(2,4-dihydroxyphenyl)-2-phenylethanone
phenylacetic acid (43)
resorcinol (44)
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2,4-dibenzyloxy-5-methoxy-acetophenone (45)
1-[2,4-bis(benzyloxy)-5-methoxyphenyl]ethanone
4-benzyloxy-benzaldehyde (46)
2,4,4´-benzyloxy-5-methoxy-chalcone (47)
(2E)-3-[4-(benzyloxy)phenyl]-1-[2,4-bis(benzyloxy)-5-methoxyphenyl]prop-2-en-1-one
2,4,4´-benzyloxy-5-methoxy-acetal-chalcone (48)
(2E)-3-[4-(benzyloxy)phenyl]-1-[2,4-bis(benzyloxy)-5-methoxyphenyl]-2-
(dimethoxymethyl)prop-2-en-1-one
phenol (49)
phenol sulphate (50)
phenyl hydrogen sulphate
phenol-4-sulphonate (51)
4-hydroxybenzenesulphonic acid
sulfurtrioxide pyridine complex (52)
oxosulphane dioxide - pyridine (1:1)
pyridine (53)
5,7,4´-trihydroxyflavone (54)
5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
5,7,4´-tri-O-TCE-sulphate flavone (55)
4-oxo-2-(4-{[(2,2,2-trichloroethoxy)sulphonyl]oxy}phenyl)-4H-chromene-5,7-diyl
bis(2,2,2-trichloroethyl) bissulfate
5,7,4´-tri-O-sulphate flavone, ammonium salt (56)
triammonium 4-oxo-2-[4-(sulphonatooxy)phenyl]-4H-chromene-5,7-diyl disulphate
quercetin-3-O-glucoside (57)
5,7-bis(benzyloxy)-2-(2,2-diphenyl-1,3-benzodioxol-5-yl)-4-oxo-4H-chromen-3-yl b-D-
glucopyranoside
quercetin-3-O-glucuronide (58)
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl b-D-
glucopyranosiduronicacid
penta-O-acetyl-b-glucopyranose (59)
1,2,3,4,6-penta-O-acetyl-b-D-glucopyranose
phenyl-b-acetyl-glucoside (60)
phenyl 2,3,4,6-tetra-O-acetyl-b-D-glucopyranoside
17
tetra-O-acetyl-1-fluoro-a-D-glucopyranosyl (61)
2,3,4,6- tetra-O-acetyl-1-fluoro-a-D-glucopyranosyl
tetra-O-acetyl-1-bromo-a-D-glucopyranosyl (62)
2,3,4,6-tetra-O-acetyl-1-bromo-a-D-glucopyranosyl
genistein-7-O-tetra-acetylglucoside (63)
5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl 2,3,4,6-tetra-O-acetyl-b-D-
glucopyranoside
tri-O-acetyl-1-bromo-a-L-quinovopyranosyl (64)
2,3,4-tri-O-acetyl-1-bromo-a-L-quinovopyranosyl
daidzein-7-O-tri-acetyl-b-L-quinovopyranoside (65)
3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl 2,3,4-tri-O-acetyl-a-L-quinovopyranoside
daidzein-7-O-tetra-acetylglucoside (66)
3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl 2,3,4,6-tetra-O-acetyl-b-D-glucopyranoside
daidzein-8,3´,5´-trideutero-7-O-b-glucoside (67)
3-(4-hydroxyphenyl-3´,5´-d2)-4-oxo-4H-chromen-8-d-7-yl b-D-glucopyranoside
ononin (68)
3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl b-D-glucopyranoside
formononetin (69)
7-hydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one
tri-O-acetyl-1-bromo-a-D-glucopyranuronic acid methyl ester (70)
2,3,4-tri-O-acetyl-1-Bromo-a-D-glucopyranuronic acid methyl ester
4´-O-Ac-daidzein (71)
3-(7-hydroxy-4-oxo-4H-chromen-3-yl)phenyl acetate
4´,8-dihydroxyisoflavone-7-O-a-D-arabinofurasine (72)
8-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl a-D-arabinofuranoside
tri-O-benzoyl-1-bromo-a-D-arabinofuranosyl (73)
2,3,5-tri-O-benzoyl-1-bromo-a-D-arabinofuranosyl
4´-O-hexanoyl-daidzein (74)
4-(7-hydroxy-4-oxo-4H-chromen-3-yl)phenyl hexanoate
perbenzoylated D-glucopyranosyl-(N-phenyl)trifluoroacetamide (75)
2,3,4,6-tetra-O-benzoyl-1-O-[(1E)-N-benzyl-2,2,2-trifluoroethanimidoyl] D-
glucopyranose
4´-O-hexanoyl daidzein 7-O-2 ,3 ,4 ,6 -tetra-O-benzoyl-b-D-glucopyranoside (76)
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4-{4-oxo-7-[(2,3,4,6-tetra-O-benzoyl-b-D-glucopyranosyl)oxy]-4H-chromen-3-yl}phenyl
hexanoate
genistein-4´-O-glucoside (77)
4-(5,7-dihydroxy-4-oxo-4H-chromen-3-yl)phenyl b-D-glucopyranoside
daizein-4´-O-glucoside (78)
4-(7-hydroxy-4-oxo-4H-chromen-3-yl)phenyl b-D-glucopyranoside
genistein-4´-O-a-D-ribofuranoside (79)
4-(5,7-dihydroxy-4-oxo-4H-chromen-3-yl)phenyl 2,3,5-tri-O-acetyl-a-D-ribofuranoside
genistein-4´-O-b-D-ribofuranoside (80)
4-(5,7-dihydroxy-4-oxo-4H-chromen-3-yl)phenyl 2,3,5-tri-O-acetyl-b-D-ribofuranoside
1,2,3,5-tetra-O-acetyl-b-D-ribofuranose (81)
daidzein-4´-O-a-L-rhamnopyranoside (82)
4-(7-hydroxy-4-oxo-4H-chromen-3-yl)phenyl a-L-rhamnopyranoside
tri-O-acetyl-1-fluoro-a-L-rhamnopyranolsyl (83)
2,3,4- tri-O-acetyl-1-fluoro-a-L-rhamnopyranolsyl
3´,5´-dideuteroformononetin (84)
7-hydroxy-3-(4-methoxyphenyl-3,5-d2)-4H-chromen-4-one
3,5-dideutero-4-methoxybenzaldehyde (85)
4-methoxy-3,5-d2-benzaldehyde
6,8,3´,5´-tetradeuterodaidzein (86)
7-hydroxy-3-(4-hydroxyphenyl-3,5-d2)-4H-chromen-4-one-6,8-d2
6,8,3´,5´-tetradeuterogenistein (87)
5,7-dihydroxy-3-(4-hydroxyphenyl-3,5-d2)-4H-chromen-4-one-6,8-d2
6,8,2´,3´,5´,6´-hexadeuterodaidzein (88)
7-hydroxy-3-(4-hydroxyphenyl-2,3,5,6-d4)-4H-chromen-4-one-6,8-d2
7-O-ethoxycarbonylpropyldaidzein (89)
ethyl 4-{[3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl]oxy}butanoate
4´-O-ethoxycarbonylmethyldaidzein (90)
ethyl [4-(7-hydroxy-4-oxo-4H-chromen-3-yl)phenoxy]acetate
4´-O-ethoxycarbonylmethylgenistein (91)
ethyl [4-(5,7-dihydroxy-4-oxo-4H-chromen-3-yl)phenoxy]acetate
7-O-ethoxycarbonylmethyldaidzein (92)
19
ethyl {[3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl)]oxy}acetate
7-O-ethoxycarbonylmethylgenistein (93)
ethyl [4-(5,7-dihydroxy-4-oxo-4H-chromen-3-yl)phenoxy]acetate
7-O-carboxymethyl daidzein (94)
{[3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl]oxy}acetic acid
7-O-Bn-genistein (95)
7-(benzyloxy)-5-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one
7-O-Bn-daidzein (96)
7-(benzyloxy)-3-(4-hydroxyphenyl)-4H-chromen-4-one
7-O-Bz-daidzein (97)
3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl benzoate
7-O-Bz-genistein (98)
5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl benzoate
2-hydroxy-4-methoxy-acetophenone (99)
1-[4-(benzyloxy)-2-hydroxyphenyl]ethanone
4-methoxymethoxy-benzaldehyde (100)
4-(methoxymethoxy)benzaldehyde
di-O-Ac-daidzein (101)
4-[7-(acetyloxy)-4-oxo-4H-chromen-3-yl]phenyl acetate
4´-O-Bz-genistein (102)
4-(5,7-dihydroxy-4-oxo-4H-chromen-3-yl)phenyl benzoate
di-O-Bz-genistein (103)
4-[7-(benzoyloxy)-5-hydroxy-4-oxo-4H-chromen-3-yl]phenyl benzoate
4´-O-TBDMS-genistein (104)
3-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-5,7-dihydroxy-4H-chromen-4-one
7,4´-di-O-TBDMS-genistein (105)
7-{[tert-butyl(dimethyl)silyl]oxy}-3-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-5-
hydroxy-4H-chromen-4-one
8-chloro-3´,4´,5,7-tetrahydroxyisoflavone (106)
8-chloro-3-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one
3-chloro-4,6-dimethoxyacetophenone (107)
1-(3-chloro-2-hydroxy-4,6-dimethoxyphenyl)ethanone
6,8-dichlorogenistein (108)
20
6,8-dichloro-5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one
8,3´-dichlorodaidzein (109)
8-chloro-3-(3-chloro-4-hydroxyphenyl)-7-hydroxy-4H-chromen-4-one
8,3´,5´-trichlorodaidzein (110)
8-chloro-3-(3,5-dichloro-4-hydroxyphenyl)-7-hydroxy-4H-chromen-4-one
daunorubicin (111)
(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-
hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
4-methoxyresorcinol (112)
1,3-dihydroxy-4-methoxybenzene
4-hydroxyphenylacetonitrile (113)
(4-hydroxyphenyl)acetonitrile
isovanillin (114)
3-hydroxy-4-methoxybenzaldehyde
2,4,4´-trihydroxy-5-methoxy-deoxybenzoin (115)
1-(2,4-dihydroxy-5-methoxyphenyl)-2-(4-hydroxyphenyl)ethanone
7-O-formylglycitein (116)
3-(4-hydroxyphenyl)-6-methoxy-4-oxo-4H-chromen-7-yl formate
ketiminium chloride intermediate of glycitein deoxybenzoin (117)
4-[2-(4-hydroxyphenyl)ethanimidoyl]-6-methoxybenzene-1,3-diol hydrochloride
glycitein-7,4´-di-O-sulphate (118)
4-[6-methoxy-4-oxo-7-(sulphooxy)-4H-chromen-3-yl]phenyl hydrogen sulphate
dihydrodaidzein-7,4´-di-O-sulphate disodium salt (119)
disodium 4-[4-oxo-7-(sulphonatooxy)-3,4-dihydro-2H-chromen-3-yl]phenyl sulphate
dihydrogenistein-7,4´-di-O-sulphate disodium salt (120)
disodium 4-[5-hydroxy-4-oxo-7-(sulphonatooxy)-3,4-dihydro-2H-chromen-3-yl]phenyl
sulphate
6,8,2´,3´,5´,6´-hexadeuterogenistein (121)
5,7-dihydroxy-3-(4-hydroxyphenyl-2,3,5,6-d4)-4H-chromen-4-one-6,8-d2
2´,3´,5´,6´,-tetradeuterogenistein (122)
5,7-dihydroxy-3-(4-hydroxyphenyl-2,3,5,6-d4)-4H-chromen-4-one
5,8,2´,3´,5´,6´-hexadeuteroglycitein (123)
7-hydroxy-3-(4-hydroxyphenyl-2,3,5,6-d4)-6-methoxy-4H-chromen-4-one-5,8-d2
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2´,3´,5´,6´-tetradeuterogenistein-7,4´-di-O-sulphate disodium salt (124)
disodium 4-[5-hydroxy-4-oxo-7-(sulphonatooxy)-4H-chromen-3-yl]phenyl 2,3,5,6-d4
sulphate
6,8,2´,3´,5´,6´-hexadeuterodaidzein-7,4´-di-O-sulphate disodium salt (125)
disodium 4-[4-oxo-7-(sulphonatooxy)-4H-chromen-3-yl 6,8-d2]phenyl 2,3,5,6-d4 sulphate
5,8,2´,3´,5´,6´-hexadeuteroglycitein-7,4´-di-O-sulphate disodium salt (126)
disodium 4-[6-methoxy-4-oxo-7-(sulphoonatooxy)-4H-chromen-3-yl-5,8-d2 ]phenyl-
2,3,5,6-d4 sulphate
daidzein-4´-O-Bn-7-O-triacetylglucuronic acid methyl ester (127)
3-[4-(benzyloxy)phenyl]-4-oxo-4H-chromen-7-yl methyl 2,3,4-tri-O-acetyl-b-D-
glucopyranosiduronate
daidzein-7-O-triacetylglucuronic acid methyl ester (128)
3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl methyl 2,3,4-tri-O-acetyl-b-D-
glucopyranosiduronate
daidzein-4´-O-sulphate-7-O-triacetylglucuronic acid methyl ester (129)
methyl 4-oxo-3-[4-(sulphooxy)phenyl]-4H-chromen-7-yl 2,3,4-tri-O-acetyl-b-D-
glucopyranosiduronate
4´-O-Bn-daidzein (130)
3-[4-(benzyloxy)phenyl]-7-hydroxy-4H-chromen-4-one
8-chlorogenistein (131)
8-chloro-5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one
6-chlorogenistein (132)
6-chloro-5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one
6,3´-dichlorogenistein (133)
6-chloro-3-(3-chloro-4-hydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one
biochanin A (134)
5,7-dihydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one
5,7,4´-tri-methoxy-genistein (135)
5,7-dimethoxy-3-(4-methoxyphenyl)-4H-chromen-4-one
6,8-dichlorobiochanin A (136)
6,8-dichloro-5,7-dihydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one
1,1',1''-(chloro-l4-sulphanetriyl)tribenzene (137)
phenolchlorosulphinate (138)
phenyl chloridosulphite
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7-O-Bn-glycitein (139)
7-(benzyloxy)-3-(4-hydroxyphenyl)-6-methoxy-4H-chromen-4-one
7-O-Bz-glycitein (140)
3-(4-hydroxyphenyl)-6-methoxy-4-oxo-4H-chromen-7-yl benzoate
7-O-Ac-daidzein (141)
3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl acetate
4´-O-Bn-genistein (142)
3-[4-(benzyloxy)phenyl]-5,7-dihydroxy-4H-chromen-4-one
4´-O-Bn-glycitein (143)
3-[4-(benzyloxy)phenyl]-7-hydroxy-6-methoxy-4H-chromen-4-one
4´-O-Bz-daidzein (144)
4-(7-hydroxy-4-oxo-4H-chromen-3-yl)phenyl benzoate
4´-O-Bz-glycitein (145)
4-(7-hydroxy-6-methoxy-4-oxo-4H-chromen-3-yl)phenyl benzoate
7-O-carboxylglycitein (146)
{[3-(4-hydroxyphenyl)-6-methoxy-4-oxo-4H-chromen-7-yl]oxy}acetic acid
4´-O-carboxylglycitein (147)
[4-(7-hydroxy-6-methoxy-4-oxo-4H-chromen-3-yl)phenoxy]acetic acid
daidzein-7-O-Bn-4´-O-tetraacetylglucoside (148)
4-[7-(benzyloxy)-4-oxo-4H-chromen-3-yl]phenyl 2,3,4,6-tetra-O-acetyl-b-D-
glucopyranoside
daidzein-4´-O-tetraacetylglucoside (149)
4-(7-hydroxy-4-oxo-4H-chromen-3-yl)phenyl 2,3,4,6-tetra-O-acetyl-b-D-glucopyranoside
daidzein-4´-O-Bz-7-O-triacetylglucuronide methyl ester (150)
3-[4-(benzoyloxy)phenyl]-4-oxo-4H-chromen-7-yl methyl 2,3,4-tri-O-acetyl-b-D-
glucopyranosiduronate
7-O-(phthalimide-N-)butylbiochanin A (151)
2-(4-{[5-hydroxy-3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl]oxy}butyl)-1H-
isoindole-1,3(2H)-dione
5-(4-aminobutoxy)-2-[4-(4-methoxyphenyl)-1H-pyrazol-3-yl]benzene-1,3-diol (152)
biochanin A daunorubicin (153)
3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-
1-yl 2,3,6-trideoxy-3-[(4-{[5-hydroxy-3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl]
oxy}butanoyl)amino]hexopyranoside
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7-O-carboxypropylbiochanin A (154)
4-{[5-hydroxy-3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl]oxy}butanoic acid
7-O-carboxypropyl-pivaloylester-biochanin A (155)
2,2-dimethylpropanoic 4-{[5-hydroxy-3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-
yl]oxy}butanoic anhydride
4´-O-ethoxycarbonylmethylglycitein (156)
ethyl [4-(7-hydroxy-6-methoxy-4-oxo-4H-chromen-3-yl)phenoxy]acetate
7-O-ethoxycarbonylmethylglycitein (157)
ethyl {[3-(4-hydroxyphenyl)-6-methoxy-4-oxo-4H-chromen-7-yl]oxy}acetate
7-O-ethoxycarbonylpropylgenistein (158)
ethyl 4-{[5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl]oxy}butanoate
7-O-carboxypropylgenistein (159)
4-{[5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl]oxy}butanoic acid
7-O-ethoxycarbonylpropyl Biochanin A (160)
ethyl 4-{[5-hydroxy-3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl]oxy}butanoate
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1. INTRODUCTION
Isoflavones are polyphenols which are found in the plant kingdom, mainly in legumes. As
many as over 870 different isoflavones have been identified in plants.1 These exist mainly
as glycosides, and to be more accurate, as 7-O-b-glycoside conjugates. In human diet, a
common source of isoflavones is soy, which is an ingredient used in numerous food
products nowadays.2 The scientific interest towards isoflavones has grown during the past
years because of their possible beneficial health effects. This can also be seen in the
growing number of the nutritional health products containing isoflavones. Connections
with the prevention of cancer, decreased alcohol consumption, prevention of osteoporosis
and effect on cardiovascular diseases have been observed.3 This, however, does not mean
that eating products containing isoflavones are the ultimate solution in preventing
diseases. In many cases, to obtain the health effects, isoflavones should be eaten in
amounts that are impossible to consume, without the risk of toxic side-effects.
Structural features
The structure of an isoflavone is composed of a 3-phenylchromen-4-one skeleton, in
which the rings are indicated with letters A, C and B, starting from the left (Figure 1). The
structure of an isoflavone differs from the structure of a flavone by the position of the
phenyl ring, B, which in the case of a flavone is in position 2 (Figure 1). Despite the
structural similarities, the chemical behaviour of these compounds differ from each other a
great deal, leading to the fact that synthetic methods for flavones cannot be used with
isoflavones as such.
Figure 1. Flavone and isoflavone skeletons
Isoflavones are a subgroup of the large isoflavonoid family which contains the following
groups: isoflavones, isoflavanones, isoflavans, isoflavanols, isoflav-3-enes, a-
methyldeoxybenzoins, rotenoids, pterocarpans, coumestans, 2-arylbenzofurans, 3-
arylcoumarins and coumaronochromones (Figure 2).4
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2-Arylbenzofurans 3-Arylcoumarins Coumaronochromones
Figure 2. Isoflavonoid family
Glycoside form
As mentioned earlier, isoflavones exist in plants mainly in their glycoside form. As an
example, we may consider a compound such as daidzin (1) (Figure 3). This is one of the
most common isoflavone in nature. Other forms of the glycosides are the malonyl-b-
glucoside and acetyl-b-glucoside.5 The b-anomer of the isoflavone glycoside is the main
stereochemical form of the compound concerned. This means that the oxygen substituent
at carbon C-1´´ (anomeric carbon) is cis to the group at highest numbered chiral carbon
atom (C-5´´), as seen in Figure 3.6 In the case of the minor stereoisomer a-anomer, the
bonds are trans to each other. In this thesis the term glycoside will be used to describe the
O-glycosides of isoflavones and term glycosidation to describe how they are synthesised.
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daidzin (1) R1=H, R2=H, R3=H
genistin (2) R1=H, R2=OH, R3=H
glycitin (3) R1=OMe, R2=H, R3=H
6´´-O-malonyl R3=COCH2COOH
6´´-O-acetyl R3=COCH3
Figure 3. Isoflavone 7-O-b-glycosides
Aglycon form
Despite the fact that isoflavones exist mainly as glycosides in nature, the study in the field
of synthesis and research is mainly concentrated on their aglycones, in other words,
isoflavones without the monosaccharide moiety. This is mainly because the isoflavone
glycosides are readily hydrolysed in mammals to aglycones. Hydrolysis can also take
place during the fermentation and germination processes of the plant products. In the
literature, both aglycon and aglucon are frequently used terms to describe this form of the
structure. In this thesis, the term aglycon is used to describe isoflavones without a
monosaccharide moiety. As an example, we may consider the structure of daidzein (4), the
aglycon form of daidzin (1) (Figure 4). Other main isoflavone aglycones are genistein (5)7
and glycitein (6)8. The common structural feature of these compounds is the phenolic OH
groups at positions 7 and 4´. This is also the structural linkage between the female
hormone estradiol-17b (7) and 7,4´-dihydroxyisoflavones (Figure 4).9 The distance
between the hydroxy groups in estradiol-17b (7) is nearly the same as in isoflavones (the
distance between OH groups at positions 7 and 4´). In theory, this could mean that
isoflavones could bind to the same receptors as estradiol-17b (7) creating functions in the
human body which are yet unknown.
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Figure 4. Structural relationship of isoflavone aglycones and estradiol-17b (7)
As a result of the hydrolysis, the formed aglycones are further metabolised to phenolic
conjugates in the human body. These include sulphates, glucuronides and
sulphoglucuronides which are highly water soluble conjugates (Figure 5). The aglycones
can also be de-methylated, reduced and oxidised (Figure 6). Neither the biological activity
nor the exact metabolic route of the metabolised compounds are fully understood. It
remains to be seen if the further metabolised compounds have a stronger biological
activity than the aglycon forms.
The following chapters will concentrate on the background of isoflavones and their
metabolites and on the synthesis of isoflavone O-conjugates which include sulphates and
glycosides. The methods for regioselective alkylation and protection will be discussed,
including the cleavage of the protecting groups. The chapter 3, Results and Discussion,
will present the completed work during this research. Methods for sulphation and
glucuronation of isoflavones, regioselective protection and selective deprotection, O-
alkylation and chlorination of isoflavones will be presented.
1.1 SOURCES OF ISOFLAVONES IN HUMAN DIET
In the previous chapter, it was stated that isoflavones exist in plants mainly as their 7-O-
glycosides, such as daidzin (1),10 genistin (2)11 and glycitin (3) (Figure 3)12. Isoflavone
glycosides can be found in various natural sources including seeds, beans, fruits, hops and
cherries.2 The common source of isoflavones is soy, containing significant amounts of
isoflavones. As an example, soy flour contains up to 2 mg/g of isoflavones.13 By
comparison, other sources contain only traces of these beneficial compounds, (mg/g). The
average daily consumption of soy protein among Chinese women in Asia was estimated to
be 36-45 g.14 This would mean a 500 g average consumption of soy products (e.g. tofu,
miso and soy milk) per day and a 40 mg daily intake of isoflavones.13,14 In Western
countries the daily consumption of soy is low, since the usual sources of protein are
animal based products.
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1.2 METABOLISM OF ISOFLAVONES
Numerous studies have been conducted concerning the metabolism of isoflavones in
mammals. These studies have mostly been based the results on various HPLC-MS data of
physiological matrices.15,16,17,18,19,20,21,22,23,24,25,26,27,28,29  There are only few GC-MS studies
owing to the required additional derivatisation steps.30,31 It is noteworthy that the
sensitivity of GC-MS is, however, better than HPLC-MS. The basic idea of the HPLC-MS
studies is to identify isoflavones and their metabolites (qualitative analysis) and compare
their concentrations in the samples, for example in urine, plasma, and serum (quantitative
analysis). In the HPLC based studies, the samples are usually hydrolysed enzymatically,
which results in misleading data concerning the identification of sulphates and
glucuronides and their concentrations in the sample. These studies often suggest that the
amount of aglycones in physiological samples from humans is predominating. As we will
see later, this is not the absolute truth. This matter should be taken into account, when
testing the biological activities of isoflavones. The reliability of the analytical procedures
suffers from the lack of suitable model compounds. These are crucial in testing the
behaviour and to find out the stability of the analytes during the analysis procedure.
At first step, isoflavone glucosides are hydrolysed by intestinal flora to their aglycones,
such as daidzin (1) to daidzein (4). In 2002 Setchell et al. proved that isoflavone
glucosides do not exist in plasma, supporting the fact that they are hydrolysed before
entering the blood stream.32 Aglycones are mainly metabolised to sulphate, glucuronide
and sulphoglucuronide conjugates, making isoflavones more water soluble, thus
improving their excretion (Figure 5).
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daidzein-7-O-glucuronide (8) R1=R2=H
genistein-7-O-glucuronide (9) R1=H, R2=OH
glycitein-7-O-glucuronide (10) R1=OMe, R2=H
daidzein-7-O-sulphate (11)
daidzein-4´-O-glucuronide (12) R=H
genistein-4´-O-glucuronide (13) R=OH
daidzein-4´-O-sulphate (14) R=H
genistein-4´-O-sulphate (15) R=OH
daidzein-7-O-glucuronide-4´-O-sulphate (16) R=H
genistein-7-O-glucuronide-4´-O-sulphate (17) R=OH
daidzein-7,4´-di-O-sulphate (18)
Figure 5. Isolated mammalian hydrophilic metabolites of isoflavones
On the other hand, these hydrophilic metabolites and aglycones can be further metabolised
to equol (19), dihydrodaidzein (20), dihydrogenistein (21), 3´-hydroxydaidzein (22) and
O-desmethylangolensin (23), although in lower amounts (Figure 6). These can then be
remetabolised to sulphates, glucuronides and sulphoglucuronides (Figure 7).
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Figure 6. Isolated reduced and oxidised mammalian metabolites of isoflavones
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Figure 7. Isolated glucuronides of reduced isoflavones
King presented the following figure describing the possible metabolic routes of
isoflavones in mammals (Figure 8).33 In the represented figure, solid arrows show the
movement of isoflavones and the dashed ones their bacterial conversion.
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Figure 8. Circulation of isoflavones in mammals33
There have also been a few studies in the field of isolation and identification of isoflavone
metabolites in rats and humans.34,35,36,37,38,39 In 2002, a study was published by Ohsawa et
al. on the mammalian metabolism of Radix puerariae isoflavonoids.40 Radix puerariae is
the root of Pueraria lobata Ohwi, a perennial plant found in Asia. The root, from which
isoflavonoids can be found, is used as a herbal medicine. Ohsawa et al. isolated various
conjugates of isoflavones, mainly conjugates of daidzein (4) and genistein (5), from urine,
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bile and feces (Table 1). They analysed the isolated compounds by using IR, MS and
NMR techniques. One interesting observation was that daidzein-7-O-glucuronide-4´-O-
sulphate (16) was detected in bile but not in urine. They thought that the reason for this
behaviour may be explained by the structure of daidzein-7-O-glucuronide-4´-O-sulphate
(16). As being a relatively large compound and with high polarity, it might be excreted
rather via bile than urine. This is important to take a notice of in the development of
analytical studies which try to estimate the total amount of isoflavones and their
metabolites by analysing urine. As mentioned earlier, the hydrolysis of HPLC samples can
give misleading results as well as if the study is based only on the analysis of urine. The
found isoflavone metabolites and their sources (e.g. urine, bile, plasma, feces) are
collected in Table 1, where it can be seen that the analytical study has concentrated mainly
on rats. The few results of human metabolism found in urine, are in contradicting. It seems
that there is no clear agreement for the sulphation and glucuronidation sites in isoflavones.
Further studies are needed by analysing human urine with controlled feeding. The use of
internal standards should also be considered.
33
Table 1. Detection of isoflavones and their metabolites from biological samples
Source/isoflavone/ Ref. Method Aglycones Sulphates Glucuronides Sulpho-glucuronides
Rat urine/puerarin 34 isolation 4 14, 18 8
Rat urine/daidzin/after hydrolysis 35 isolation 4, 19 20, 22
Rat urine/daidzin, daidzein 38 isolation 4 14, 18 8 16
Rat urine/daidzin, daidzein 40 HPLC 4, 19, 20, 22 14, 18 8
Rat bile/ daidzin, daidzein 40 HPLC 4 14, 18 8 16
Rat plasma/ daidzin, daidzein 40 HPLC 4 14, 18 8
Rat feces/ daidzin, daidzein 40 HPLC 4
Rat urine/ daidzin, daidzein 38 HPLC 4 14, 18 8
Rat bile/ daidzin, daidzein 38 HPLC 4 14, 18 8 16
Human urine/soy supplement 39 isolation 4, 5, 6, 20, 23 11 8, 9, 10, 12, 13,
24, 25
16, 17
Rat urine/genistein 36 isolation 5 15 9 17
Rat urine/genistein 36 HPLC 5 15 9
Rat bile/genistein 36 HPLC 9 17
Rat urine/genistein/after hydrolysis  37 isolation 19, 21
Human urine/soy supplement 31 GC/MS 4, 5, 19, 23 11/14, 26/15,
28/29, 30/31,
18, 27, 32, 33
8/12, 9/13, 34/35,
25/36, 37, 38, 39
16, 17, 40, 41
Human urine/soy supplement 19 LC/MS 4, 5 11, 26, 14, 15 8, 9, 12, 13, 37,
38
16, 17
Bold numbers indicate isolated and detected compounds (See Figure 5, 6 and 7 for details)
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1.3 BIOLOGICAL ACTIVITY OF METABOLITES
There exist various publications on the biological activity of isoflavones and their possible
health effects.41,42,43,44,45,46,47,48,49 Biological activity studies have been mainly concentrated
on daidzein (4), genistein (5) and also on their glucosides because these are readily
hydrolysed in mammals (rats and humans) to aglycones. It has to be taken into account,
that the actual active compound might be one of the metabolites (e.g. glucuronides,
sulphates, reduced or oxidised) rather than aglycones. As an example we may consider
daidzein-7,4´-di-O-sulphate (18), the main bile metabolite in rats. Daidzein-7,4´-di-O-
sulphate (18) is a potent inhibitor of sterol sulphatase.50 Sterol sulphatase is the enzyme
that releases estrogen from its inactive sulpho form and by doing this makes the estrogen
available in the human body. Interaction with the estrogen receptor has also been studied
with glycitein (6)51 and with daidzein or genistein sulpho and sulphoglucuronides.46
1.4 SYNTHESIS OF ISOFLAVONES AND THEIR CONJUGATES
The need for the development of synthetic methods for the title compounds is obvious.
Especially authentic samples for the confirmation of the isolated plant conjugates and their
human metabolites are necessary for the testing of the possible biological activity of the
identified compounds. This chapter concentrates on the synthesis of  the most common
isoflavones; daidzein (4), genistein (5) and glycitein (6), and on the synthesis of their
various O-conjugates, which are divided into the separated subchapters (Chapters 1.4.2-
1.4.5). First, the synthesis of starting isoflavone aglycones will be introduced. Next,
methods available for sulphation, glycosidation, deuteration and regioselective O-
substitution of isoflavones as well as chlorination, will be discussed.
1.4.1 SYNTHESIS OF ISOFLAVONE AGLYCONES
The first synthesis of isoflavone aglycones was published in 1925 by Baker et al.52 They
synthesised various 2-substituted isoflavones starting from 2-hydroxydeoxybenzoins. This
was the beginning of the synthetic study of isoflavones.  53,54 The two most popular
synthetic pathways to isoflavones are the deoxybenzoin (2-hydroxyphenyl benzyl
ketone)55,56,57,58,59,60,61,62 and the chalcone63,64,65,66,67,68,69,70,71,72 routes. These routes are
presented in Schemes 5 and 7, respectively. Other not that commonly used routes include
the conversion of a flavanone (Scheme 1),73,74,75 epoxidation of a chalcone (Scheme 2),76,77
condensation of an enamine with salicylaldehydes (Scheme 3)78 and the well known
Suzuki cross-coupling reaction (Scheme 4),79 all yielding isoflavones.
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Scheme 1. Conversion of flavanone to isoflavone
O
O
OBn O
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Reagents and conditions: i) BF3-Et2O, benzene, +10 °C ii) HCl, AcOH
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Scheme 2. Isoflavone from epoxidated chalcone
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Reagents and conditions: i) Benzene, reflux ii) CrO3, pyridine, RT
Scheme 3. Isoflavone by condensation of enamine
O
O
O
O
i
Reagents and conditions: i) Tl(NO3)3, MeOH, CHCl3
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Reagents and conditions: Pd(PPh3)4, Na2CO3, benzene, reflux
Scheme 4. Isoflavone by Suzuki cross-coupling
Deoxybenzoin route
The deoxybenzoin intermediate is first formed by standard electrophilic substitution of
phenol with benzyl cyanide (Houben-Hoesch reaction)80 or phenylacetic acid (Friedel-
Crafts acylation), 81 followed by cyclisation (Scheme 5).
R1 OH
R3
R5
R4 NH
R1 OH
R3
R4HCl
O
R1 OH
R3
R4
O
R1 O
R3
R4
Houben-Hoesch
Friedel-Crafts
acylation
R2 R
2
R2R
2
Reagents and conditions: Houben-Hoesch:(R5=CN) HCl, ZnCl2, Et2O, RT i) H+/H2O. Friedel-Crafts:
(R5=COOH) BF3-Et2O. ii) BF3-Et2O, MeSO2Cl, DMF
i
ii
Scheme 5. Synthesis of deoxybenzoins by the Houben-Hoesch reaction or the Friedel-
Crafts acylation
Houben-Hoesch
The synthetic approach using the standard Houben-Hoesch reaction employes ZnCl2 as a
Lewis acid,55,57,80,88 which has been substituted by BF3-Et2O complex in one case.56 The
BF3-Et2O complex acts as a solvent and a catalyst ‘all in one’, which can be considered to
be an advantage over the use of traditional ZnCl2 where a dry solvent (ether) is needed.
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Friedel-Crafts acylation
Panasenko et al. presented the following reaction scheme for Friedel-Crafts acylation of
2,4-dihydroxydeoxybenzoin (42) starting from phenylacetic acid (43) and resorcinol
(44).81 It should be noted that the reaction involves a release of water and hydrogen
fluoride. The latter can lead to cleavage of acid sensitive groups.
HO OH
COOH
HO O
O
BF2BF3-Et2O
-H2O, -HF, -Et2O
OHHO
O
EtOH, H2OBF3-Et2O
(44)
(43)
(42)
Scheme 6. Friedel-Crafts acylation of resorcinol with phenylacetic acid
The last step in the deoxybenzoin route is cyclisation, which can be carried out in many
ways. The additional carbon atom needed for the ring formation can be introduced, for
example, by the treatment with one of the following combination of reagents BF3-
Et2O/DMF/MeSO2Cl,82,55,60 BF3-Et2O/DMF/PCl5,61,62 Zn(CN)2/HCl,58 HCO2Et/Na,83
HC(OEt)3/pyridine56 and dimethoxydimethylaminomethane.84 One option for the
cyclisation reaction is to use ethoxalyl chloride (ClCOCO2Et) which gives the isoflavone
after the decarboxylation step.85,86 In some cases the substitution and ring-closing steps
can be combined in a one-pot reaction.60,61,87 The effectiveness of the one-pot reaction
depends heavily on the structures of the starting materials. In some cases, the ring closing
has been carried out under microwave irradiation without any notable improvements to the
yields.88,89 The beauty of the deoxybenzoin route is the straightforwardness of the reaction
as there is no need for the protection of phenolic OH-groups.
In the majority of the  publications, daidzein (4) has been prepared employing the Friedel-
Crafts acylation.60,61,90,91 Among them are three publications on glycitein (6) one using the
deoxybenzoin route89 and two others the chalcone approach.67,70 In the case of genistein
(5) the situation is more complex. There are reports in which genistein (5) has been
produced by one-pot Friedel-Crafts acylation (BF3-Et2O),60 whereas some studies have
applied the Houben-Hoesch approach.61,88 The yields are usually high when the
deoxybenzoin route is used and as mentioned before, the procedure is rather
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straightforward. Although the Houben-Hoesch reaction is often criticised of being
laborious, our experiences do not confirm that argument.
Chalcone route
The chalcone intermediate is obtained by the condensation of protected acetophenones and
benzaldehydes under basic conditions (Scheme 7). The formed chalcone is then
oxidatively rearranged usually with thallium (III) salts.
In the synthesis of glycitein (6), acetophenone (45) and benzaldehyde (46) give chalcone
(47) (Scheme 7). This is further oxidatively rearranged with thallium (III) salts to give the
acetal (48) which is cyclised in acidic conditions to give glycitein (6).67
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MeO
OBn
O
BnO OBn
MeO
O
OBn
BnO OBn
MeO
O
OBn
CH(OMe)2
OHO
MeO
O
OH
i
ii
iii
Reagents and conditions: i) 50% aq. KOH, EtOH, RT ii) trimethyl orthoformate, Tl(NO3)3,
MeOH, RT iii) Pd/C, H2, MeOH/acetone (1:1), RT iv) conc. HCl, MeOH, reflux
iv
(47)
(48)(6)
(45) (46)
Scheme 7. Synthesis of glycitein (6) by chalcone route
1.4.2 SULPHATION OF ISOFLAVONES
There are only a few examples of the sulphation of isoflavones in the literature.50,92,93
However, several publications concerning the sulphation can be found on flavones and,
not surprisingly, numerous on phenols. There are multiple ways to sulphate phenols and
these methods can be employed as tools when designing the sulphation reactions for
isoflavones and their conjugates.94 Most of the methods are based on the complexes of
sulphur trioxide (SO3), either with pyridine (Scheme 9), DMF, TCE (Scheme 10), or DCC
(Scheme 11). SO3 by itself is an aggressive electrophilic reagent that rapidly reacts with
any organic molecule containing an electron donating group without any selectivity or
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control.95 In the case of phenol (49), SO3 can give either sulphate esters (50) or
sulphonates (51) (Scheme 8).96
OH OSO3H OH
SO3H
SO3
(50) (51)(49)
Scheme 8. Reaction between phenol and SO3
The reactivity towards organic compounds can be controlled by coupling SO3 with a
Lewis base, usually with pyridine or DMF. The reactivity and stability of the SO3
complex, as for sulphation, depend on the strength of the base used.94 Weaker the base,
greater the partial positive charge on sulphur atom on the SO3 complex. For example,
DMF is a weaker base than pyridine, leading to the fact that SO3.DMF is a stronger
sulphating agent than the corresponding pyridine complex, but still mild enough to
produce only sulphate esters. One common procedure for making a pyridine sulphur
trioxide complex (52) is the reaction between pyridine (53) and chlorosulphonic acid
(ClSO3H) either with isolation of the formed complex (Scheme 9) or in situ.97,98
N
ClSO3H NSO3
Reagents and conditions: i) pyridine, ClSO3H, Et2O,  0 °C
i N
H
Cl
(53) (52)
Scheme 9. Preparation of pyridine sulphur trioxide complex
TCE complex
There are also some examples of the use of 2,2,2-trichloroethyl (TCE) ester of
chlorosulphuric acid as a sulphation agent for flavones and estrones (Scheme 10).99,100
Here, TCE acts as a protecting group for the sulphate ester and can be cleanly cleaved by
hydrogenolysis with ammonium formate (HCOONH4) and palladium on charcoal (Pd/C)
without affecting the sulphate moiety itself. The stability of the aryl TCE sulphates in the
highly acidic conditions is remarkable. It also creates possibilities in the purification step
by changing the polarity of the compound. This sulphation route could especially be
useful in the situation were further reactions are carried out after the sulphation step. In
theory, this method could also be used in the regioselective sulphation of isoflavones.
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Scheme 10. Sulphation of flavone by TCE-complex
DCC
In the flavone field, the sulphations have been mainly performed under
dicyclohexylcarbodiimide acid (DCC) activated reaction conditions, or by using the
sulphur trioxide trimethylamine complex (SO3-Me3N), resulting in mixtures of
sulphates.101,102,103,104,105 In the reaction where sulphuric acid is used, the role of DCC is to
work as an activator. Hoiberg et al. presented a possible mechanism for the DCC activated
reaction with sulphuric acid and phenol in 1969 (Scheme 11).106 They noticed that the
formed O-sulphonylisourea is stable only for 30 seconds after the formation. Barron et al.
were not able to obtain sulphated flavonoids using the DCC sulphuric acid method.103
However, they found that changing sulphuric acid to tetrabutylammonium hydrogen
sulphate (TBAHS) afforded sulphated flavonoids in moderate yields. The reason for this
behaviour might be explained by the salt formation between the O-sulphonylisourea and
tetrabutylammonium cation which also stabilises the formed sulphate ester.
41
N
C
N
S
O
O
OHHO
NH
C
NH
OS
O
O
O
Sulphuric acid + DCC
DMF
ROH
NH
C
NH
OS
O
O
O
R O
H
DMF
S
O
O
OHRO
NH
C
NH
O
DMF
Scheme 11. DCC activation of sulphuric acid
Recently Jones et al. reported a synthesis for a mixture of quercetin sulphates using SO3-
DMF complex as sulphation reagent.107 The yields for compounds separated by HPLC
ranged from 0.8% to 16.3%.
As for the isoflavones, in 1996 Peterson et al. reported the synthesis of genistein-4´-O-
sulphate (15) using sulphuric acid in the presence of DCC in DMF.92 In 1997 Wong et al.
described a synthesis for a mixture of daidzein-4´-O-sulphate (14) and daidzein-di-O-
sulphate (18) using the SO3-DMF complex.50 Both of the above presented publications
were published without any data on yields, making it difficult to judge the efficiency of
the suggested methods. Fairley et al. synthesised daidzein-di-O-sulphate (18) and mono
sulphates (11, 14) using protecting group chemistry (e.g. TBDMS) and SO3-pyridine
complex.93 The approach with TBDMS for isoflavones is quite a different method as the
phenolic OH groups are directly and regioselectively protected with TBDMS, after which
the sulphation reaction is carried out.
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1.4.3 GLYCOSIDATION OF ISOFLAVONES
The literature presented in this chapter mainly focuses on the synthesis of isoflavone 7 and
4´ O-glycosides. This is due to the fact that the monosaccharide moieties are generally
located at the position 7-O and 4’-O. These glycoside derivatives can be found in nature,
as mentioned earlier in the general introduction part, but these derivatives have also been
synthetically prepared. The methods described for the synthesis of glucosides can be used
in the synthesis of isoflavone glucuronides. There are only a few publications describing
the synthesis towards isoflavone glucuronic acids.108,109 One possibility for the synthesis
of isoflavone glucuronides is a method described by Bouktaib et al. in 2002 (Scheme
12).110 They were able to oxidise flavonol glucoside (57) into flavonol glucuronide (58) by
using protecting groups (e.g. benzyl group) on phenols and a catalytic amount of
tetramethylpiperidine nitroxyl (TEMPO), as a free radical generator, in the presence of
sodium hypochlorite (NaOCl) as an oxidant.
OBnO
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O
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O
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O
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OH
OH
OHO
OH
OH
 i
ii
Reagents and conditions: i) NaOCl, TEMPO ii) Pd/C, H2
(57) (58)
Scheme 12. Oxidation of flavonol glucoside to flavonol glucuronide
To understand the stereoselectivity of the glycosidation reactions, different types of
mechanisms are introduced. There are two kinds of glycosidation reactions for phenols,
those which give only one stereoisomer and those which give mixtures of anomers. The
stereospecific reactions are mainly accepted to be SN2 type reactions, while those giving
mixtures of anomers are based on the formation of a carbocation (SN1). As a simple
example we may consider the reaction between glucose and methanol in a presence of an
acid catalyst (Scheme 13).111 The reaction is initiated by the cleavage of water which
creates a resonance stabilised carbocation which further reacts with nucleophile. The
attack of the nucleophile can happen from both sides of the anomeric carbon, leading to a
mixture of a and b anomers, b anomer being the major product.
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Scheme 13. Glycosidation of glucose with methanol in the presence of acid catalyst
The situation is different when the OH groups are acetylated or benzoylated in the
monosaccharide unit. The acetyl or benzoyl group at the C-2 position creates the so-called
neighbouring group effect which means that the carbonyl group forms a five-membered
ring with the anomeric carbon (Scheme 14).112 The nucleophilic attack is forced to take
place from the b face, leading to the b anomer. The stereochemistry of the starting sugar
does not affect the formation.
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Scheme 14. Neighbouring group effect in glycosidation reaction leading to b-anomer
The situation is not as simple in the case of phenols, which are much weaker nucleophiles
than alcohols. First we will start by a brief introduction to the methods that have been used
in the synthesis of phenolic glycosides. The main glycosidation method for phenols is the
reaction of phenol with glycosyl fluoride or bromide under various conditions. These
include the use of a phase transfer catalyst,113,114,115,116,117,118 Koenigs-
Knorr,119,120,121,122,123,124,125,126 silver triflate,127,128 BF3-Et2O129,130 and Cp2ZrCl2-AgBF4.131
Yamaguchi et al. noticed that in the case of BF3-Et2O, the stereochemistry can be
controlled by using various amino bases, and suggested a mechanism for this
stereochemical control (Scheme 15).129 The b-anomer is favoured when an amine base is
present. This is caused by the removal of the proton from the equatorial position in the
intermediate before the transition to axial form, which gives the a-anomer.
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Scheme 15. Stereoselectivity of glycosidation reaction in the presence of base
Lee et al. noticed in their glycosidation experiments with penta-O-acetyl-b-glucopyranose
(59), that 50% of the formed phenyl-b-acetyl-glucoside (60) was isomerised in the
presence of BF3-Et2O to its a anomer during 10 hours at room temperature.132 The use of
triethylamine exhibited the isomerisation. On the other hand, Jensen et al. reported only
minor changes in the a/b ratio during four hours, in the presence of BF3-Et2O.127
However, they did not test the effect of the base in their studies and it should be noted that
they used tetra-O-acetyl-a-D-glucopyranosyl fluoride (61) as monosaccharide. The true
nature of the BF3-Et2O mediated reaction mechanism is still unclear, as is also the
influence of the glycoside halide stereochemistry.
Yu et al. used a mixture of a/b acetyl and benzoyl protected glycosyl
trifluoro(phenyl)acetamides in the presence of trimethylsilyl trifluoromethanesulphonate
(TMSOTf) to obtain b glycosides in moderate yields.133,134 Clerici et al. reported the case
of penta-O-acetyl-b-glucopyranose (59) where the acetyl group at anomeric position acts
as a leaving group. This reaction also follows the mechanism presented in Scheme 14,
leading to b anomers.135 In this reaction, tin tetrachloride (SnCl4) forms an adduct with
AcO-, derived from penta-O-acetyl-b-glucopyranose (59). Clerici et al. noted that the use
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of the a anomer glycoside as a starting material led to lower yields compared to the b
anomer.135
With two-phase or Koenigs-Knorr reaction conditions, the glycosidation products are
usually obtained as one stereoisomer although the use of Koenigs-Knorr conditions does
not exclude the possibility of carbocation formation.119 The possible side reactions in a
two-phase reaction are the b-elimination and hydrolysis of halide.136
In the synthesis of phenolic sugars, the key factor is the stereochemistry. Reaction
conditions, the stereochemical purity of the glycosyl donor, as well as reactivity with
phenol have to be considered in order to achieve high yields with selective a:b ratio. It
also has to be understood that in many cases the a:b ratio can depend on factors such as
solvent, temperature, leaving group and substitution stage of phenol. Although the
syntheses described above might work well for phenols it is not certain that they work for
isoflavones.
In conclusion, it can be said that the two-phase and Koenigs-Knorr methods produce
strereochemically pure compounds. The use of methods where a carbocation is formed,
mainly BF3-based yields are usually higher for glycosidation but the stereoselectivity
depends heavily on several factors. These are the nucleophility of the phenol, solvent used,
presence of base and reaction temperature. When considering the synthesis of glycosides it
has to be decided which factor is of major importance, the high yield or the
stereoselectivity of the reaction.
1.4.3.1 SYNTHESIS OF ISOFLAVONE-7-O-GLYCOSIDES
This chapter describes the methods used in the synthesis of isoflavone-7-O-glycosides by
regioselective glycosidation or by using protecting groups. The first regioselective
glycosidation for isoflavones was introduced by Zemplén et al. in 1943.137 They
synthesised genistin (2), by reacting genistein (5) with tetra-acetyl-O-a-D-glucopyranosyl
bromide (62) in a 9% KOH solution in acetone. The reaction gave genistin (2) in a 17%
yield after the hydrolysis of the acetyl groups on glucoside moiety. The intermediate,
genistein-7-O-tetra-acetylglucoside (63), was not isolated. Several similar types of
reactions, without the isolation of the acetyl protected intermediate, have been reported.138
Selective glycosidation at position 7-O is possible because of the difference in the acidity
between the hydroxy groups 7 and 4´ in polyhydroxyisoflavones (Figure 4). Nishiyama et
al. used a 2M KOH solution and tri-O-acetyl-a-L-quinovopyranosyl bromide (64) in
acetone to synthesise daidzein-7-O-tri-acetyl-b-L-quinovopyranoside (65) in a 32%
yield.66 It should be noted that they were able to isolate the acetyl protected intermediate.
In 1998 Lewis et al. reported a method for synthesising several isoflavone-7-O-b-
glucosides in yields varying from 40% to 42%.139 These included the synthesis of daidzin
(1) and genistin (2) using a two-phase system with tetrabutylammonium bromide
(Bu4N+Br-) as a phase transfer catalyst. Furthermore, they did not isolate the intermediate
products, isoflavone-7-O-tetra-acetyl glucosides (63, 66). From that, it can be assumed
that this method is not suitable for reactions where the acetyl protecting groups are needed
on the glucoside unit for further reactions, as an example, sulphation at the 4´-O-position.
In the same year Lewis et al. published another method for the glycosidation of
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isoflavones at position 7-O without isolating the acetylated intermediate.140 Now they used
solid-liquid conditions, to produce daidzein-8,3´,5´-trideutero-7-O-b-glucoside (67) in a
40% yield. In 2001 Wang et al. reported a synthesis for ononin (68) starting from
formononetin (69).141 They performed the glycosidation step using potassium carbonate
(K2CO3) as a base in a solvent mixture of DMF/acetone with dodecyltrimethylammonium
bromide (DTMAB) as a phase transfer catalyst. The yield for acetylglucoside isoflavone
was 85%. Glycitin (3) was synthesised regioselectively in 1996 by Nógrádi et al. applying
the Koenigs-Knorr method,67 where phenol is reacted with a a-glucoside halide using
silver salts, usually silver carbonate (Ag2CO3), or pyridine as an acid acceptor to give b-
glycoside.119 The yield for the glycosidation step was 17%. Needs et al. investigated the
same method to synthesise daidzein-7-O-b-D-glucuronide (8) by using tri-O-acetyl-a-D-
glucopyranuronic acid methyl ester bromide (70).108 Moreover, they noticed that without
the protection of the 4´-OH, the desired reaction did not take place. Instead of the target
compound, only 4´-O-Ac-daidzein (71) with unidentified groups at position 7 were
detected. When acetyl protection was used at position 4´-O, the yield of the
glucuronidation step was 30%. Koenigs-Knorr reaction has been used in several other
syntheses of isoflavone glucosides with protecting groups.138,142
In 1999, Shiozaki published a method for synthesising 4´,8-dihydroxyisoflavone-7-O-a-
D-arabinofurasine (72) using allyl protection.143 The glycosidation was performed using n-
butyllithium (n-BuLi) as a base in THF to generate the isoflavone lithium salt which was
further reacted with tri-O-benzoyl-1-bromo-a-D-arabinofuranosyl (73) to yield 26% of the
corresponding protected glycoside. It should be noted that the stereochemistry remained
the same during the reaction, meaning that the reaction mechanism is not SN2. The reason
for this stereochemistry is the neighbouring group effect which leads to the attack from the
a face, since the Bz and Br are trans to each other in starting material (see previous
chapter for details). One option for the glycosidation of isoflavones is a trifluoroacetamide
approach, where the protected isoflavone is reacted with glycosyl (N-
phenyl)trifluoroacetamide (mixture of a and b anomers) in the presence of BF3-Et2O to
give the corresponding isoflavone glycoside up to 90% yields (Scheme 16).144,109
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Scheme 16. Glycosidation of isoflavone by trifluoroacetamide monosaccharide
As a conclusion, it can be said that there is no selective method available for the synthesis
of isoflavone-7-O-b-glycosides, in which the hydroxy groups at the monosaccharide
moiety are protected with acetyls. It seems that the only practical methods are those using
a protecting group at position 4´-O on the isoflavone.
1.4.3.2 SYNTHESIS OF ISOFLAVONE-4´-O-GLYCOSIDES
Isoflavone-4´-O-glycosides are rare in the nature, and so are the synthetic publications. In
fact, there are only a few publications describing the synthesis of them. In 1954, Bognár et
al. introduced a method for synthesising genistein-4´-O-b-glucoside (77), also known as
sophoricoside (77), using p-nitro-benzyl protection at position 7-O.145,146 The yield for the
glycosidation step, performed with a 2.5% KOH solution, was only 6%. 44 years later
Lewis et al. reported a regioselective method for the 4´-O-b-glycosidation of isoflavones
(77, 78) using 18-crown-6 as a phase transfer catalyst and t-BuOK as a base in
acetonitrile.147 However, the reported NMR data is rather confusing. The signal at 9.60
ppm in the spectrum of sophoricoside (77) indicates that the 4´-OH is unconjugated. It
seemed that in case of genistein (5) they in fact synthesised genistin (2). This will be
discussed later in Chapter 3.6.3. In 2001, Boryski et al. published a method for
synthesising genistein-4´-O-ribofuranosides (79, 80) (Scheme 17).148 They used SnCl4 and
1,2,3,5-tetra-O-acetyl-b-D-ribofuranose (81) for regioselective synthesis. The reaction
gave a mixture of a and b products in a ratio of 1:2. The yield of b-anomer after column
chromatographic purification was 54%. These results are in agreement with the previously
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published method for phenols, which used penta-O-acetyl-b-glucopyranose (59) as
starting material (Chapter 1.4.3).135 Boryski et al. did not investigate the effect of the
stereochemistry of the starting monosaccharide.148 Instead, they noticed that the use of a
acetonitrile/CH2Cl2 solvent mixture in the reaction improved the yields notably.
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Scheme 17. Synthesis of genistein-4-O-glycosides
Nishiyama et al. used TMS derivatisation for isoflavone to enhance the nucleophility in
the synthesis of daidzein-4´-O-a-L-rhamnopyranoside (82) using tri-O-acetyl-1-fluoro-a-
L-rhamnopyranolsyl (83) as the monosaccharide.66 By this way, they were able to obtain a
mixture of 4´-O-mono and 7,4´-di-O products in 47% and 73% yields respectively.
However, this gives a confusing total yield of 120%, which means that the results are
somewhat unreliable. The rest of the publications rely on the use of protecting groups.149
It seems that there is no available method for selective glycosidation at the position 4´-O.
All the previously described methods give either mixtures of mono and di products or
mixtures of a and b anomers.
1.4.4 DEUTERATION OF ISOFLAVONES
Among many applications, deuterated (D=2H) compounds are generally used in the
HPLC-MS and GC-MS studies as reference compounds. By deuterating the desired
compounds, these will behave in chromatography like their non-deuterated analogues
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having the same retention time. However, the difference can be seen in the mass spectrum
as they are distinguished by their molecular mass. To obtain mass spectral reliability, there
have to be at least three deuterium atoms present in the reference molecule in order to
increase the molecular mass above the M+1 and M+2 of the corresponding non-deuterated
analogue.150 The degree of deuteration is expressed by the term of isotopic purity. It means
the percentage of the specific protons exchanged to the deuterons. In the presence of three
deuteriums the isotopic purity should be 100% in order to obtain accurate results in mass
spectrometry. In reality, it is normal to introduce four or more deuteriums to the molecule
and by doing this to ensure that at least three protons are changed completely. With these
properties, the deuterated molecules can be added to a sample and used as internal
standards in qualitative and quantitative analysis. Deuterated isoflavones can be divided
into two categories according to the method of production. The first method is to introduce
the deuterium atoms by total synthesis.151 This can be done in a way that starting materials
are deuterated which leads to a deuterated product. The only total synthetic route reported
for deuterated isoflavones uses a chalcone approach (Scheme 18). Al-Ani et al. started the
synthesis for 3´,5´-dideuteroformononetin (84), which is 4´-O-methylated analogue of
daidzein (4), from 3,5-dideutero-4-methoxybenzaldehyde (85).151
O
OMe
D D
BnO OH
O
BnO OH
O
D
D
OMe
O
O
Bn
OMe
D
D
O
O
HO
OMe
D
D
i
ii, iii
iv
Reagents and conditions: i) KOH/EtOH, RT ii) pyridine,Ac2O iii) Tl(NO3)3-H2O,MeOH, KOH, RT
iv) cyclohexene,  Pd(OH)2/C, EtOH, reflux
(85)
(84)
Scheme 18. Synthesis of 3´,5´-dideuteroformononetin (84) by chalcone route
Deuterated compounds can also be obtained by deuterating the target molecule. This can
be done by using deuterated acids as reagents, mainly deuterated trifluoro acetic acid
(CF3COOD) or a phosphoric acid – boron trifluoride – deuterium oxide complex (D3PO4-
BF3/D2O). The exchange rate of the protons to deuterons follows an order 8>3´,5´>6>2´,6´
for example to daidzein (4).152 CF3COOD has been used to synthesise 6,8,3´,5´-
tetradeuterodaidzein (86) by refluxing for 9 days153 and 6,8,3´,5´-tetradeuterogenistein
(87) by refluxing for 6 days154 (Scheme 19).
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Scheme 19. Deuteration of isoflavones by CF3COOD
By the using D3PO4-BF3/D2O reagent, deuteriums can be introduced even to the less
active 2´ and 6´ positions at B-ring.155 In the case of daidzein (4), to exchange the protons
2´ and 6´ required 7 days in autoclave at 100°C to obtain 6,8,2´,3´,4´,5´-
hexadeuterodaidzein (88) (Scheme 20).156
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Scheme 20. Synthesis of 6,8,2´,3´,4´,5´-hexadeuterodaidzein (88) by D3PO4-BF3/D2O
The D3PO4-BF3/D2O reagent has also been used in the deuteration of polyhydroxy
flavones.157 Previously flavones have been deuterated with NaOH/D2O to produce a d2 or
d3 compound in low isotopic purity.158,159 As can be seen from the literature, there is a
need for a rapid method, producing d6 deuterated isoflavones in high yield and isotopic
purity.
1.4.5 ISOFLAVONES SUBSTITUTED AT POSITION 7-O OR 4´-O
In this chapter, the topics concerning the regioselective O-alkylation and protection of
isoflavones at the 7 and 4’O-positions will be considered. Isoflavones can be O-
substituted using typical procedures described to phenols but the case is not always
necessarily that straightforward as for phenols owing to many O-positions in isoflavones.
Although the selectivity in reactions can be achieved with the aid of the protecting groups,
their use can be time consuming. In some cases, protecting groups are essential, like in a
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molecule bearing several reactive sites, which differ more or less in their reactivity.
However, a selective O-substitution of isoflavones can be simply achieved without the use
of protecting groups. Therefore one has to be careful when planning the synthetic route
and deciding whether the selective synthesis or use of protecting groups is more
advantageous. There are several reports concerning the selective O-substitution of
isoflavones.90,149,160,161,162,163,164,165,166,167,168,169 Most of them rely on the acidity difference
between phenolic OH groups in isoflavones again, at positions 7 and 4’.
Different computer programmes can be used to estimate the pKa values of the OH groups
on isoflavones.170,171 One of these, Sparc v 3.1, gives the following calculated pKa values
for OH groups at positions 7 and 4´ in dry DMSO: daidzein (4) 13.87 and 15.64, genistein
(5) 10.54 and 12.96, and for glycitein (6) 13.73 and 16.60 respectively. From these values,
it can be seen that the acidic difference between the hydroxy groups is almost one hundred
fold in all of these compounds. When the calculation is conducted in non-aqueous DMF,
the ratio between the pKa values of the hydroxy groups stays the same. In genistein (5),
the OH group at position 5 is hydrogen bonded to the carbonyl group at position 4,
decreasing its reactivity. It is not possible to calculate a pKa value for the OH group at
position 5 because in the algorithm of these computer programmes the hydrogen bonding
option is not included.
Under carefully modified basic conditions, one can introduce an alkyl or acyl group
selectively to either positions 7-O or 4´-O, in moderate yields. Common solvents in the
substitution reactions of isoflavones include DMF,93,109,160,161,162,167,168 pyridine,164
DMSO,165 acetone,88,163 propanol169 and also aq. KOH166. There are numerous bases one
can use, but the best one so far, for the regioselective alkylation, seems to be potassium
tert-butoxide (t-BuOK) under non-aqueous conditions.93,109,160,167,168 This may be due to
the fact that t-BuOK is a strong base, capable of deprotonating OH groups on isoflavones,
but being bulky at the same time. It has been reported that in some cases the use of an aq.
alkaline solution (e.g. NaOH, KOH) may result in the decomposition of the C-ring.172,163
1.4.5.1 CARBOXYLIC ACID CHAIN DERIVATIVES
Carboxylic acid chain derivatives have been synthesised to develop analytical processes
and for studying the possible biological activity.160,166,169 As mentioned earlier, the
regioselectivity of these following reactions is based on the acidic difference between the
OH groups.
The first selective synthesis towards isoflavone carboxylic acid chain derivatives was
reported for daidzein (4) in 1989.168 In this publication, 7-O-
ethoxycarbonylpropyldaidzein (89) was synthesised by using t-BuOK as a base in DMF
(Scheme 21). The protected carboxylic acid derivative was obtained in 85% yield, after
stirring for 10 days at room temperature.
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Scheme 21. Selective alkylation of daidzein (4) at position 7-O
By using this method Al-Maharik et al. produced a series of mono-O-alkylated carboxylic
acid chain isoflavones, at both 7-O and 4´-O positions in moderate yields (Scheme 22).160
The common factor of the above reactions is that they are made in two steps in situ, the
first step being the formation of the desired potassium phenolate and the second one the
addition of the alkyl halide. By controlling the amount of the base (t-BuOK), one can
either create mono phenolate (7-OH) or di-phenolate (7-OH and 4´-OH). In the case of
diphenolate, the regioselectivity is obtained by the strong nucleophility of the 4´-
phenolate.
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Scheme 22. Selective alkylation of isoflavones at positions 7-O and 4´-O
Wang et al. reported a sonochemical synthesis for synthesising 7-O-
ethoxycarbonylmethylgenistein (93) in 85% yield, using K2CO3 as a base in acetone.163
All the previously reported synthetic methods for isoflavone carboxylic acid chain
derivatives use halocarboxylic acid ethyl esters as starting materials. After ether
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formation, the formed isoflavone carboxylic acid ester is hydrolysed to the corresponding
isoflavone carboxylic acids under acidic or basic conditions.160,163
In 2000, Rooke et al. introduced a method for synthesising various daidzein-7-O-
carboxylic acids.90 They used halocarboxylic acids as starting materials. It is noteworthy
that if the carboxylic acid group is unesterified, the amount of base has to be increased. By
using 2 equivalents (eq.) of base, 2 M KOH in acetone, they were able to produce 7-O-
carboxylic acids in yields varying from 20% to 55%. The next year the same group
published another study where they synthesised more carboxylic acid chain derivatives.166
This time they used free carboxylic acid again but also their ethyl esters. It seemed that
there was no remarkable difference in the yields independent whether the carboxylic acid
had been protected or not. The yields varied from 9% to 21% for the free carboxylic acids,
and when ethyl esters were used, the variation was between 2% and 36%. No explanations
were given for these yield variations. Kohen et al. also used unprotected carboxylic acid in
the synthesis of 7-O-carboxymethyl daidzein (94).169 The product was obtained in 16%
yield by refluxing daidzein (4) in n-propanol with sodium n-propylate (made in situ) and
bromoacetic acid.
1.4.5.2 PROTECTING GROUPS FOR ISOFLAVONES
The introduction of the protecting group to isoflavones can be done by the same methods
as used for the O-substitution, as discussed in the previous chapter. The common
protecting groups used in the protection of isoflavones are benzyl (Bn),149,164 p-
nitrobenzyl,146 benzyl ester (Bz),164,173 acetyl (Ac),108 hexanoyl,109,144 allyl142,143 and
tetrabutylmethylsilyl (TBDMS)93,161. These groups are well described in the literature as
protecting groups for phenols.174 The most challenging step for isoflavones is, however,
deprotection. As already mentioned, isoflavones are protected mainly in the synthesis of
glycosides, which cause restrictions for the used cleavage methods. The discussion of the
literature concerning the protection is divided into subgroups based on the site of the
protection, 7 or 4´ hydroxy group. The deprotection methods are introduced in their own
subchapter.
Protection at position 7-O
As we know, the hydroxy group at the position 7 is a hundred times more acidic than the
OH group at the position 4´. Based on this fact, several different ways to introduce the
protecting group selectively to position 7-O have been reported. In 1968 Farkas et al.
synthesised 7-O-Bn-genistein (95) using 2 eq. of K2CO3 and 1 eq. of BnCl in DMF. They
obtained the product in 73% yield.149 Other methods which also rely on the use of
relatively mildly basic conditions have been reported, although in lower yields. Nakayma
et al. introduced synthesis in 1978 for 7-O-Bn-daidzein (96), using 2% aqueous KOH as a
base and 1.4 eq. of BnCl in DMF/acetone.164 The product, which structure was confirmed
by 1H NMR, was obtained in 45% yield. In the same publication methods for synthesising
7-O-Bz-daidzein (97) and 7-O-Bz-genistein (98) were presented.164 Instead of KOH in
these studies pyridine acts as a solvent and a base. 7-O-Bz-daidzein (97) and 7-O-Bz-
genistein (98) were obtained in 46% and 58% yield, respectively.164 However, they only
reported the UV-VIS spectra and elemental analysis for these compounds. More detailed
spectroscopical methods (1H NMR) should be applied as the possibility of
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transesterification can not be excluded. This phenomen will be discussed in the following
chapter. In 2003, Jung et al. introduced a total synthetic approach to prepare 7-O-Bn-
daidzein (96).175 The synthesis started from benzyl protected 2,4-dihydroxyacetophenone
(99) and methoxymethoxy protected 4-hydroxybenzaldehyde (100) (Scheme 23). By using
the chalcone route they obtained 7-O-Bn-daidzein (96) in 49% yield.175
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Scheme 23. Synthesis of 7-O-Bn-daidzein (96) by the chalcone route
Protection at position 4´-O
There are a few studies describing the protection of isoflavones at position 4´-O. Needs et
al. prepared 4´-O-Ac-daidzein (71) by selective hydrolysis of di-O-Ac-daidzein (101).108
They used imidazole as a base and obtained the product in 94% yield. Li et al. used a
similar approach as they used transesterification to produce 4´-O-hexanoyl daidzein (74)
and 4´-O-Ac-daidzein (71) from the corresponding diesters in 94% and 96% yields,
respectively.144 They also used imidazole as a base and thiophenol (PhSH) as a
nucleophile for transesterification in N-methyl-pyrrolidone (NMP). Transesterification has
also been used in the synthesis of 4´-O-Bz-genistein (102).173 Genistein (5) (1 eq.) was
reacted with di-O-Bz-genistein (103) (1 eq.) in pyridine with Ag2CO3 to produce 4´-O-Bz-
genistein (102) (2eq.) in 96% yield (Scheme 24). This kind of transesterification reaction
is also known in the chemistry of flavones.176
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Scheme 24. Transesterification of genistein (5)
In 2003, Fairley et al. introduced a regioselective method for the silylation (TBDMS) of
daidzein (4) at position 4´-O by using t-BuOK as a base in DMF in 60% yield.93 The same
year Szeja et al. synthesised 4´-O-TBDMS-genistein (104) by partial deprotection of the
corresponding 7,4´-di-O-TBDMS-genistein (105) with phthalic anhydride in 45% yield.161
Deprotection of ester and ether bonded protecting groups of isoflavones
The deprotection of phenolic protecting groups are well described in the literature.174
Usual ways for the deprotection of benzyl protections from phenols are the reductive
methods based on the introduction of hydrogen. Protecting groups with an ester linkage
are easily hydrolysed under basic and acidic conditions.174 The hydrolysis normally leads,
in case of isoflavone glycosidation reactions, also to the cleavage of the acetyl groups
from the monosaccharide unit.108,109,142
The debenzylation of isoflavones is usually performed with Pd/C, using H2 or HCOONH4
as a source of hydrogen. The yields are usually moderate, despite the fact that the
reduction of the double bond on C-ring could be suspected. Jung et al. reported that by
controlling the hydrogen pressure, debenzylation can be performed selectively.175 Under a
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hydrogen pressure 1.4 bar (20psi) they were able to selectively cleave the Bn-group. When
the pressure was increased to 2.1 bar (30 psi) the Bn group was cleaved and the double
bond was reduced.175 The majority of publications, where hydrogenation for debenzylation
has been used, do not report the hydrogen pressure or how the pressure is controlled.64,149
Al-Ani et al. used cyclohexene as a source of hydrogen in the synthesis of 3´,5´-
dideuteroformononetin (84) in high yield.151 Kim et al. performed debenzylation for
isoflavones with sulphur conjugates at position 2, by using BF3-Et2O-Me2S reagent in
dichloromethane.59 The reagent was used because of the possible danger for poisoning of
palladium catalyst by sulphur. The use of Lewis acids in the debenzylation of phenols is
also known in the literature.174
Lewis acids have also been used in the cleavage of allyl group in the presence of acetyl
groups. Shozaki used RhCl3 in EtOH to cleave allyl groups from isoflavone acetyl
protected glycoside in 73% yield (Scheme 25).142,143
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Scheme 25. Cleavage of allyl protections in the presence of acetyl protected glycoside
As mentioned earlier, the ester linked protecting groups are easily hydrolysed in basic and
acidic conditions. One other option is transesterification. Li et al. found out that by using
PhSH and imidazole in NMP, they could cleave the hexanoyl protection from 7-OH,
selectively, in the presence of benzoyl protection on isoflavone glycoside (Scheme 26).144
58
OO
O
O
O
O
O
OBzBzO
OBz
Reagents and conditions: i) PhSH, imidazole, NMP, RT
S
O
O
O
O
O
O
OBzBzO
OBz
O
HO
S
O
Scheme 26. Cleavage of the hexanoyl group by transesterification
The method is based on the formation of PHS- anion, which leads to the transesterification
reaction with hexanoyl group.
The removal of the TBDMS group has been performed with 1 M Bu4N+Br- in THF and a
75% aqueous solution of Bu4N+Br- in THF has also been used.93,161
Lee et al. performed a partial demethylation of isoflavone-C-8-glucoside by using Me3SiI
in refluxing CH3CN.177
In conclusion, it can be stated that there are only a few regioselective methods for the
protection of isoflavones. More work should be done, especially in the field of the
protection of the 4´ hydroxy and selective deprotection in the presence of sensitive
moieties.
1.4.6 CHLORINATION OF ISOFLAVONES
Chlorinated isoflavones and flavones also can be found in cultivated broths of
Streptomyces.178,179,180,181 Streptomyces are bacteria which are mainly found in soil, 182
where they take part in the decomposition of organic materials. These bacteria are also
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used in pharmaceutical studies to produce medicines, for example antibiotics containing
chlorine.182 In the nature Streptomyces are not the only ones responsible of the
chlorination of isoflavones. Recently, Kuruto-Niwa et al. reported on the possibility of
isoflavone chlorination during a water purification process, caused by sodium
hypochlorite.183 As chlorinated isoflavones are formed in the nature, their biological
activity should be taken into consideration. It is already known that chlorinated
isoflavones possess antioxidant activity.184
There are a few synthetic publications among the literature concerning chlorinated
isoflavones. Tökes synthesised 8-chloro-3 ,´4´,5,7-tetrahydroxyisoflavone (106) by starting
from 3-chloro-4,6-dimethoxyacetophenone (107) via the chalcone route (Scheme 27). 185
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Scheme 27. Synthesis of 8-chloro-3 ,´4´,5,7-tetrahydroxyisoflavone by the chalcone route.
The deoxybenzoin route has been used to produce chlorinated isoflavones, employing the
Friedel-Crafts acylation and Houben-Hoesch reaction, from chlorinated starting
materials.56,60 In some publications chlorinated isoflavones have been obtained via
conversion of flavones.73,74,75 Recently Kuruto-Niwa et al. published a one step method
for the synthesis of 6,8-dichlorogenistein (108), 8,3´-dichlorodaidzein (109) and 8,3´,5´-
trichlorodaidzein (110) using sodium hypochlorite (NaOCl) with yields varying from 8%
to 65%.183 They were not able to control the chlorination stage. Unidentified mono and di
chlorinated isoflavones have been observed in the reaction between isoflavones and
hypochlorous acid (HOCl).186,187 The use of NaOCl,188. as well as chlorine
(Cl2),188,189,190,191 tert-butyl hypochlorite (t-BuOCl)188,192 and sulphuryl chloride
(SO2Cl2)188,189 are common chlorination reagents in the synthesis of chlorinated phenolic
compounds. It is known that these reactions often lead to the mixture of chlorinated
compounds.
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2. AIMS OF THE STUDY
The metabolism and the biological activity of isoflavones in humans are unclear. As we
have now learned from the previous chapters, the metabolic route of the isoflavones is
complicated and the synthesis of these metabolic compounds is demanding. The aim of
this study was to design, synthesise and develop new synthetic methods for human
isoflavone metabolites. And by conducting this, to contribute to the research which is
carried out in order to understand the role of these compounds in the human body.
In the very beginning of these studies there were no methods available for the direct
synthesis of desired metabolic derivatives which include isoflavone sulphates,
glucuronides and sulphoglucuronides. The possibility for new applications in the even
more expanded area of these synthesised compounds was considered further and hence, it
was realised that a rapid and efficient method for the deuteration of isoflavone disulphates
is necessary.
From the beginning, it was obvious from the literature that the protecting groups would
play an important role in the synthesis of the highly polar isoflavone metabolites. Due to
this fact, it was decided to investigate several different methods for the protection. The
demands concerning the protection were the regioselectivity of the synthesis and the mild
cleavage in the presence of monosaccharide or sulphate moieties.
A part of this study concentrated on the development of a synthetic route towards
isoflavone daunorubicin conjugates in collaboration with Professor Skaltsounis from
University of Athens, Greece. Daunorubicin (111) is a drug used to prevent the progress of
cancer. The basic idea to link daunorubicin (111) with isoflavone was to obtain a
molecule, which could overcome the known problem with cancer cells called multi drug
resistance (MDR). Different approaches were investigated to obtain this target molecule.
Some interesting observations were noted during the study. One example of these was the
chlorination of genistein (5) with thionyl chloride (SOCl2). This unusual reaction was
investigated further, also with other isoflavones, in order to understand the nature of this
reaction, and also to develop a synthesis for chlorinated isoflavones that might have
antioxidant features.
The results as well as the methods, of these aims are reported in the following chapters.
3. RESULTS AND DISCUSSION
This chapter presents the research work conducted in this study. The aims and how they
were reached will be discussed each in their own chapter with conclusions. The methods
of the unpublished work will be presented in Chapter 4, Experimental.
3.1 SYNTHESIS OF STARTING MATERIALS
Daidzein (4),60 dihydrodaidzein (20),193 dihydrogenistein (21)193 and equol (19)194 were
synthesised according to the previously published methods. Dihydrogenistein (21) was
also synthesised by catalytic hydrogenation (see Chapter 4). Genistein (5) was prepared by
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the Houben-Hoesch route and one-pot method.60 For glycitein (6) there were only a few
published methods, two using chalcone route and one using deoxybenzoin route.67,70,89
From the literature it was known that the deoxybenzoins are usually solid, however in the
published deoxybenzoin route synthesis for glycitein (6), the corresponding deoxybenzoin
was isolated as an oil.89 The synthesis of glycitein (6) was started from deoxybenzoin by
the Houben-Hoesch route.55,80 The starting materials in the synthesis of glycitein (6) by
the Houben-Hoesch route are 4-methoxyresorcinol (112) and 4-hydroxyphenylacetonitrile
(113) (Scheme 28). 4-Methoxyresorcinol (112) is not a commercially available compound,
so it was synthesised from isovanillin (114), as described previously.195 The Houben-
Hoesch reaction, with 4-methoxyresorcinol (112) and 4-hydroxyphenylacetonitrile (113),
gave the desired deoxybenzoin (115) after the hydrolysis step. Ring cyclisation was
performed by BF3.Et2O, MeSO2Cl in DMF, first reported by Bass in 1976.82 The
cyclisation step gave glycitein (6) and partially formylated 7-O-glycitein (116), which was
hydrolysed by 0.5M NaOH. After neutralisation, glycitein (6) was obtained as off white
solid in moderate yield (see Chapter 4).
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i, ii
iii, iv
v
Reagents and conditions: i) H2O2 30%, SeO2, t-BuOH, RT ii) K2CO3, MeOH, RT. iii) ZnCl2,
HCl, Et2O, RT iv) 10% HCl, reflux v) BF3.Et2O, CH3SO2Cl, DMF +50 °C to +100 °C
(114) (112) (113)
(115)(6)
Scheme 28. Synthesis of glycitein (6) by the Houben-Hoesch route
The Houben-Hoesch mechanism to deoxybenzoin is considered to start from a reaction
between the cyano group and HCl.80 Here, the mechanism is proposed for the synthesis of
2,4,4´-trihydroxy-5-methoxydeoxybenzoin (115), starting from 4-
hydroxyphenylacetonitrile (113). The formed chloronitrile adduct coordinates to the Lewis
acid, ZnCl2 (Scheme 29). This formed complex then reacts with 4-methoxy-resorcinol
(112) by aromatic electrophilic substitution. As seen from the mechanism, the role of
ZnCl2 is only to work as a catalyst, however in practice the amount of ZnCl2 is nearly at
the equivalent level.55,57 The formed ketiminium chloride (117) is hydrolysed with acidic
H2O to give 2,4,4´-trihydroxy-5-methoxydeoxybenzoin (115).
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Scheme 29. Proposed mechanism for synthesis of 2,4,4´-trihydroxy-5-
methoxydeoxybenzoin (115) by the Houben-Hoesch reaction
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3.2 SYNTHESIS OF ISOFLAVONOID DISULPHATES
The goal was to develop a method for the sulphation of various polyhydroxy
isoflavonoids. These isoflavonoid O-sulphates, which are also human metabolites, could
be used in the research of isoflavone metabolism and to contribute in understanding the
biological activity of isoflavonoid O-sulphates.
All the previously published sulphation methods have yielded mixtures of isoflavone
mono and disulphates.50,92 As we know, there are multiple ways to introduce SO3 into the
OH group of phenol (See Chapter 1.4.2). Only few of these methods fulfilled our criteria
which were selectivity of the reaction, simple procedure and work up. One critical aspect
was the solubility of the starting isoflavonoids. From the previous experiences it was
known that solvents, such as DMF and pyridine dissolve isoflavones well. Both of these
solvents are known to form complexes with SO3 which are then used in the synthesis of
sulphate esters (See Chapter 1.4.2). The sulphation of isoflavones was started with a
SO3.pyridine complex (52) made in situ. The reaction conditions were first optimised for
daidzein (4) since its disulphate has been isolated from rat urine (Scheme 31).38 Fairley et
al. also used SO3 pyridine complex (52) in their method to produce daidzein di and mono
sulphates (11, 14, 18). The sulphation reaction proceeded well with daidzein (4) but the
isolation of the formed daidzein-7,4´-di-O-sulphate (18) seemed to be a problem. As seen
in the Scheme 30, the formed sulphate ester forms a salt with protonated pyridine.196
HO OS
O
O
O
N HNSO3
Scheme 30. Sulphation of phenol by the pyridine sulphur trioxide complex
It is common to use inorganic bases in order to release the sulphate ester from its pyridine
salt. Sulphate ester is then isolated as a potassium or sodium salt.197,198 From the 1H NMR
it was clear that the sulphation of daidzein (4) had taken place (seen as a shift of the
aromatic protons ortho to phenol) and that no by-products were present. The only
impurities were the salt residues of the used base (NaHCO3) in the isolation step and
traces of pyridine. Options for the purification due to the highly polar nature of the
daidzein-7,4´-di-O-sulphate (18) disodium salt were reverse phase (RP-18) and gel
filtration, also known as size exclusion chromatography. Recrystallisation was also
investigated, but due to the high amount of salts and the solubity of the formed sulphate in
water, these attemps were unsuccessful. The use of reverse phase chromatography, solid
phase extraction or preparative RP-18 TLC did not lead to pure compounds. It was
decided to try gel filtration. The optimal gel was found to be Sephadex LH-20. Water was
chosen as an eluent in the gel filtration process, as the formed daidzein-7,4´-di-O-sulphate
(18) disodium salt was readily soluble in water. The retention of the daidzein-7,4´-di-O-
sulphate (18) disodium salt was followed by RP-18 plates eluting with MeOH:H2O (4 : 1).
Evaporation of the combined fractions, containing the target molecule, gave the desired
compound in moderate yield. This presented reaction method was applied to genistein (5).
It was observed that the hydrogen bond between the OH at position 5 and carbonyl at
position 4 in genistein (5) was strong enough to inhibit sulphation at position 5. Thus no
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protection was needed to obtain the genistein-7,4´-di-O-sulphate (27) disodium salt. As a
result of these successful results with daidzein (4) and genistein (5), the sulphation method
was introduced also to minor isoflavone metabolites that could form disulphates in a
human. These were glycitein (6) (Scheme 31), dihydrodaidzein (20), dihydrogenistein (21)
(Scheme 32) and equol (19) (Scheme 33). All of the above compounds gave their
corresponding disulphates in moderate yields (I).
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Reagents and conditions: i) ClSO3H, pyridine, -16 ° to RT ii) 5% NaHCO3, RT
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Scheme 31. Synthesis of isoflavone-di-O-sulphate disodium salts
Reagents and conditions: i) ClSO3H, pyridine, -16 ° to RT ii) 5% NaHCO3, RT
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Scheme 32. Synthesis of isoflavanone-di-O-sulphate disodium salts
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Scheme 33. Synthesis of equol-di-O-sulphate disodium salt
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Another approach investigated to access di-O-sulphated isoflavonoids was the use of a
solid supported synthesis in which a polymer bound SO3.pyridine complex is used as a
sulphation agent. This method should provide an easy purification step by simple filtration
of the used reagent. However, in our experience no sulphation was observed at all. This
may be due to the steric hindrance of the polymer chain. The commercially available
DMF.SO3 and pyridine.SO3 complexes were also examined. The results, compared to the
in situ prepared pyridine SO3 complex (52), were not satisfying. Only partial sulphation
was observed with these commercially available complexes. The TCE protected
sulphation method was not tested in this case as the required hydrogenolysis step had been
seen to lead to the partial reduction of the double bond on C-ring.
3.3 SYNTHESIS OF DEUTERATED ISOFLAVONE DISULPHATES
Deuterated isoflavones can be used in HPLC-MS studies of isoflavones and their
metabolites.150 Isotopically labelled di-O-sulphated isoflavone derivates are useful tools
for further understanding the biological activity as well as their behaviour in the analysis
and isolation process of the biological samples. These labelled di-O-sulphated isoflavones
could be used as internal standards in physiological samples in order to investigate their
chemical stability as well as the obtained yield after the isolation from the samples and
hence determine the accuracy of the analysis results.
The aim was to develop a low cost, rapid and clean synthesis towards deuterated
isoflavone disulphates. The reasons for the deuteration to be carried out before the
formation of the sulphate ester are the possible hydrolysis under highly acidic conditions
and the low solubility of the corresponding disodium salt. As known from the literature,
CF3COOD is capable of deuterating daidzein (4) to give 6,8,3´,5´-tetradeuterodaidzein
(86) when refluxed for 9 days.153 It was also known that the use of D3PO4-BF3/D2O under
high temperature and pressure is required to obtain 6,8,2´,3´,5´,6´-hexadeuterodaidzein
(88).156 Since the handling and preparing of the D3PO4-BF3/D2O reagent is uncomfortable,
giving moderate yields,156 it was decided to use CF3COOD as a deuterating agent instead.
Isoflavones were predeuterated by evaporation from D2O/acetone solution to exchange the
phenolic protons to deuteriums.152 The deuteration of the aromatic protons was performed
under microwave irradiation in order to obtain the required temperature and pressure for
the reaction. With this approach, all three isoflavones were obtained as d6 deuterated
analogues with high isotopic purity and high yields after the recrystallisation step. In
genistein-d6 (121), the deuterium atoms at C-6 and C-8 are labile,155 and hence the back
change was done by refluxing 6,8,2´,3´,5´,6´-hexadeuterogenistein (121) in a solution of
0.5% CH3COCl/MeOH for 10 min to give 2´,3´,5´,6´-tetradeuterogenistein (122). The
identity and the purity of the compounds were verified by HPLC-MS (ESI+), 1H and 13C
NMR techniques. Only traces of M-1 were detected in ESI+ leading to an isotopic purity
over 90%. The sulphation of these compounds was performed as described previously in
the Chapter 3.1. All the deuterated analogues were stable under these reaction conditions
and the desired deuterated isoflavone disulphates were obtained in moderate yield
(Scheme 34) (II). The isotopic purity of the compounds were confirmed by ESI- and 1H
and 13C NMR analysis.
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Scheme 34. Synthesis of deuterated isoflavone-di-O-sulphate disodium salts
3.4 SYNTHESIS OF DAIDZEIN-7-O-b-D-GLUCURONIDE-4´-O-SULPHATE
Daidzein-7-O-b-D-glucuronide-4´-O-sulphate (16) is one of the known isoflavone human
metabolities.39 However, the biological activity of this compound in human body is still
unclear. To confirm the structure of the isolated analogue and to provide a tool for the
study of the biological activity of this compound, daidzein-7-O-b-D-glucuronide-4´-O-
sulphate (16) was synthesised.
A selective glucuronation at position 7-OH was explored according to the earlier reported
method for isoflavone-7-O-glucosides.139 This, however, did not give the expected acetyl
glucuronide conjugate. From this, and previous observations,108 it was clear that the
protection was indeed needed for a reaction of this kind. Hence, it was decided to
investigate the use of benzyl protection at the position 4´-OH, due to its stability under the
used reaction conditions, and also due to its selective cleavage. TBDMS protection was
also tested but the cleavage resulted to be very problematic and no expected product could
be isolated. The glucuronidation at the position 7-OH was performed with the two-phase
reaction described earlier for phenols,113,115 and also by the Koenigs-Knorr reaction which
has been reported for daidzein (4).108 When comparing these two methods, there was no
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notable difference in the yields, but due to its simpler performance the two-phase reaction
was selected.
Debenzylation of the daidzein-4´-O-Bn-7-O-triacetylglucuronic acid methyl ester (127)
was first carried out with Pd/C and H2, but it resulted in a partial reduction of the double
bond in the C-ring. The use of HCOONH4, instead of H2, as source of hydrogen did not
solve the problem. This undesired reaction was prevented by using earlier reported
debenzylation for tyrosine with thioanisole/TFA (Scheme 35).199 By using this successful
‘push and pull’ method for the debenzylation, all the acetyl groups as well as the methyl
ester were stable under these conditions.
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Scheme 35. Debenzylation of (127) by the “push and pull” method
The sulphation of the daidzein-7-O-triacetylglucuronic acid methyl ester (128) was
successfully performed with pyridine-SO3 complex made in situ, as reported earlier in
Chapter 3.1 for isoflavonoid di-O-sulphates. The hydrolysis of the acetyl groups and the
methyl ester was first carried out with 1M NaOH in acetone. Probably due to the low
solubility of the (129), the hydrolysis resulted in an unidentified mixture of products. The
sulphation step and the hydrolysis of the acetyl groups and the methyl ester were carried
out in situ to give daidzein-7-O-b-D-glucuronide-4´-O-sulfate (16) disodium salt in 41%
yield (Scheme 36) (III).
68
OHO
O
OH
OHO
O
O
OO
O
O
O
OAc
AcO
AcO
O
O
OO
O
OH
O
OAc
AcO
AcO
O
O
OO
O
OSO3Na
O
OAc
AcO
AcO
O
O
OO
O
OSO3Na
O
OH
HO
HO
ONa
O
i, ii
iii, iv
v
vi, vii
viii, ix
Reagents and conditions: i) t-BuOK, DMF, RT. ii) BnCl, RT iii) 1 eq. a-acetobromoglucuronide
methyl ester, K2CO3, Bu4NBr, CHCl3, H2O iv) 1 eq. a-acetobromoglucuronide methyl ester v)
thioanisole, CF3COOH vi) ClSO3H, pyridine, -16 °C vii)  5% NaHCO3 viii) ClSO3H, pyridine, -16
°C ix) 0.5 M Na2CO3, pH 10, RT
(4) (130)
(127)
(128)
(129)
(16)
Scheme 36. Synthesis of daidzein-7-O-glucuronide-4´-O-sulphate disodium salt (16)
3.5 SYNTHESIS OF CHLORINATED ISOFLAVONES
Chlorinated isoflavones and flavones have been found in the cultivated broths of
Streptomyces.178,180,181 The common factor of these isolated chlorinated isoflavones is that
they all have a hydrogen bonded OH group at the position 5 (Figure 9).
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Figure 9. Isolated isoflavone chlorides from cultivated broths
The synthetic methods for these chlorinated compounds have mainly been based on a total
synthesis or electrofilic aromatic substitution assisted by Cl+.183,185 A selective
chlorination of genistein (5) was observed during the synthesis of genistein acyl chloride
derivate by thionyl chloride and it was decided to further investigate this fascinating
reaction. This observation could lead to an alternative way to synthesise selectively
chlorinated isoflavones.
First, a series of reactions was made with isoflavones to observe their behaviour in neat
thionyl chloride. The reactions with daidzein (4) and glycitein (6) gave unidentified
mixtures of chlorinated compounds while genistein (5) and biochanin A (134) behaved
completely differently, since selectively chlorinated compounds were isolated. A common
factor of genistein (5) and biochanin A (134) is the hydrogen bonded hydroxy group at
position 5 capable for intramolecular hydrogen bond with C=O group. In nature, this
hydrogen bonded hydroxy group can be seen as an essential property between the
chlorinated isoflavones, isolated from cultivated broths (Figure 9).182
To rule out the possibility that chlorination is a consequence of a reaction between thionyl
chloride and the OH groups, genistein (5) was protected with methyl iodide (MeI) to give
5,7,4´-trimethoxy-genistein (135). It seemed, according to HPLC-MS, that the
chlorination proceeded in spite of the methylation, although more slowly than with
genistein (5) and without selectivity. The loss of the selectivity after the methylation of the
5-OH may be a consequence of the absence of the hydrogen bond between hydroxy group
at position 5 and carbonyl at position 4. Methylation, however, does not prevent the
participation of the free electron pair of the oxygen at position 5, which might be the key
factor in the reaction (Scheme 37).
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Scheme 37. Proposed mechanism in the chlorination of 5,7,4´-trimethoxy-genistein (135)
by SOCl2
Further experiments were conducted with resorcinol, phloroglucinol and
trihydroxyacetophenone. A mixture of various unidentified chlorinated products were
obtained without any selectivity.
The reaction between genistein (5) and SOCl2 was investigated with HPLC-MS and 1H
NMR. It was observed that the reaction proceeded first to the 8-chlorogenistein (131)
(Scheme 38). Neither prolongation of the reaction time nor heating of the reaction mixture
lead to 6,8-dichlorogenistein (108). Since it is a well-known fact that the reactions with
SOCl2 can be catalysed by a tertiary amine, in our case we investigated the effect of
Et3N.200 From these results it was seen that the presence of a catalytic amount of Et3N
slowed the reaction notably. In addition, extra signals in the 1H NMR spectrum indicated a
reaction between SOCl2 and Et3N. This was further confirmed by conducting the reaction
only with SOCl2 and Et3N yielding the same signals in the 1H NMR spectrum.
Moore et al. studied the chlorination of 4a-methyl-1,3,9-triphenyl-4aH-fluorene using
thionyl chloride and dimethyl sulphoxide.201 We also applied this method in our reaction
with genistein (5) by varying the concentration of DMSO. The reaction indeed proceeded,
but gave various chlorinated products. These products were not isolated or analysed since
the desired selectivity of the chlorination was not obtained. In their article Moore et al.
also proposed the precursor of the a-chlorosulfide which is formed from the reaction
between sulphoxide and thionyl chloride.201 This precursor is well known from the Swern
oxidation reaction where DMSO is activated with oxalyl chloride.202
6,8-Dichlorogenistein (108) was obtained in moderate yield by repeated evaporation and
addition of the fresh SOCl2, (Scheme 38) (IV). Interestingly, with biochanin A (134), only
dichlorinated product (136) could be isolated.
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Scheme 38. Synthesis of isoflavone chlorides
In the HMBC (1H-13C) spectrum of (131), couplings between the proton H-6 and carbons
C-8, C-4a, C-5, C-7 were clearly seen, again indicating the chlorination at C-8 position
(Scheme 38). In the 13C NMR spectra of 8-chlorogenistein (131) and 6, 8-
dichlorogenistein (108), the effect of the chlorine atom as an electron-withdrawing group
was clearly seen from the shifting of the signals. The carbons ortho to the chlorine atom
experienced a decrease in electron density resulting in deshielding by 4.0-4.5 ppm. On the
other hand, the carbon bearing the chlorine atom showed an increase in electron density
resulting in shielding by 3.6-5.1 ppm. In both cases, EI mass spectra indicated that the
chlorine atom(s) are located on A-ring. For 8-chlorogenistein (131), clear peaks at 304 m/z
(M+), 186 m/z (A-ring) and 118 m/z (B-ring) were detected whereas for 6,8-
dichlorogenistein (108), the peaks at 338 m/z (M+), 220 m/z (A-ring) and 118 m/z (B-ring)
were observed. Similarly for 6,8-dichlorobiochanin A (136) peaks at 352 m/z (M+), 220
m/z (A-ring) and 132 m/z (B-ring) were observed. Peaks with higher m/z are the
molecular ion of the compound concerned and the lower m/z peaks are the result of the
retro Diels-Alder fragmentation patterns respectively. The previously published mass
spectra of 8-chloro-3´,4´,5,7-tetrahydroxyisoflavone (106) show similar fragmentation
patterns as obtained for our compounds.179 The 13C NMR spectra were compared with the
previously published spectra of isolated genistein chlorine adducts.178 From the previously
published spectrum it was clearly seen that in the case of 6,8-dichlorogenistein (108), the
13C NMR spectrum was incomplete, missing a significant amount of signals.
Anyanwutaku et al. reported only 8 signals whereas from our spectrum, the total of 13
signals could be assigned, otherwise the spectral data were in agreement with ours.
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No mechanism for this type of reaction is known in the literature. Indeed, few publications
can be found suggesting mechanistic approaches for chlorination of this kind, mainly
concentrating on the repeated pathways. Carre et al. reported the following reaction
equation for chlorination of phenols.203 It is based on the reaction of three equivalent of
phenol and two equivalent of SOCl2 producing 1,1',1''-(chloro-l4-sulphanetriyl)tribenzene
(137), 3 C6H5OH + 2 SOCl2 = (OHC6H4)3SCl + SO2 + 3 HCl. The formed 1,1',1''-(chloro-
l4-sulphanetriyl)tribenzene (137) readily decomposes as follows, (OHC6H4)3SCl =
(OHC6H4)S + OHC6H4Cl. When this equation is considered from a mechanistic point of
view, the following suggestion is presented (Scheme 39).
Scheme 39. Proposed mechanism for the reaction between phenol and SOCl2
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This mechanistic approach is convenient when dealing with small molecules as the
formation of 1,1',1''-(chloro-l4-sulphanetriyl)tribenzene (137) species is sterically possible
after repeated reactions of phenol at the sulphur of SOCl2. However, in our case, where the
sterically hindranced molecule is concerned, a different approach for the mechanism has
to be applied.
Bissinger et al. studied the reactions of phenols with SOCl2, trying to produce phenyl
chlorosulphinate (138).204 They reported that when using 2 eq. of the phenol with 1 eq. of
SOCl2, traces of p-chlorophenol was obtained instead of the desired product (Scheme 40).
OH
OH
Cl
O
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Cl
O
(138)
Scheme 40. Reaction between phenol and SOCl2 resulting in p-chlorophenol
This is clear evidence from their report that the reaction is not taking place at the phenolic
hydroxyl group excluding this approach from our mechanism. The two options for the
mechanism are proposed, both based on aromatic electrophilic substitution. Both ways
lead also to the excretion of sulphur monoxide.205 The first one is electrophilic substitution
to the sulphur at SOCl2 (Scheme 41). The other one is the attack of the aromatic ring
directly to the chlorine in SOCl2 followed by the expulsion of SOCl.
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Scheme 41. Proposed mechanism for the chlorination of genistein (5) by SOCl2
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3.6 SELECTIVE SYNTHESIS OF ISOFLAVONE O-CONJUGATES
This chapter concentrates on the selective synthesis of various mono-O-conjugated
isoflavones. These include protected isoflavones as well as carboxylic acid chain
conjugates. Protecting groups were studied in connection with the synthesis of isoflavone
glucoside and glucuronide conjugates. Isoflavone carboxylic acid chain derivatives were
synthesised for two different purposes. The first was to synthesise glycitein
carboxymethyl conjugates, which could be used in the production of glycitein antibodies
in the development time resolved fluorescent immunoassay (TR-FIA) for glycitein (6).
TR-FIA is a sensitive method for detecting isoflavones from biological samples on a nano
molar (nmol/l) scale.206,207 This method has already been used with other isoflavones,
daidzein (4) and genistein (5).169,206,207 The second was to use carboxylic acid chain as a
linker between isoflavone and daunorubicin (111) to produce a molecule which could be
used in the study of MDR (Scheme 50).
3.6.1 REGIOSELECTIVE PROTECTION AND DEPROTECTION OF ISOFLAVONES
Different protecting groups for phenolic OH-groups at isoflavones were investigated
during this study. The protecting groups were chosen on the basis of their stability under
basic conditions. The cleavage of these protecting groups in the presence of acid sensitive
substituents, such as sulphate or monosachharide moieties was also a critical aspect.
Deprotection should also be possible to be performed selectively in the presence of other
protecting groups, for example cleavage of the benzyl protection in the presence of acetyl
protection.
The following protecting groups were investigated: benzyl (Bn), benzoyl (Bz), acetyl (Ac)
and t-butyldimethylsilyl (TBDMS)93. All these protecting groups can be introduced to
isoflavones regioselectively using t-BuOK as a base (see Chapter 4) (Scheme 42). These
protected isoflavones are useful in the reactions where a direct selective introduction of
the desired group is not possible. The use of these protecting groups enables the
production of selectively conjugated isoflavones.
76
O
O
R1
R2
R3
R4
(4) R1=R4=OH, R2=R3=H
(5) R1=R3=R4=OH, R2=H
(6) R1=R4=OH, R3=H, R2=OMe
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R2
R3
R4
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O
R1
R2
R3
R4
(96)   R1=OBn, R2=R3=H, R4=OH
(95)   R1=OBn, R2=H, R3=R4=OH
(139) R1=OBn, R2=OMe, R3=H, R4=OH
(97)   R1=OBz, R2=R3=H, R4=OH
(98)   R1=OBz, R2=H, R3=R4=OH
(140) R1=OBz, R2=OMe, R3=H, R4=OH
(141) R1=OAc, R2=R3=H, R4=OH
(130) R1=OH, R2=R3=H, R4=OBn
(142) R1=R3=OH, R2=H, R4=OBn
(143) R1=OH, R2=OMe, R3=H, R4=OBn
(144) R1=OH, R2=R3=H, R4=OBz
(102) R1=R3=OH, R2=H, R4=OBz
(145) R1=OH, R2=OMe, R3=H, R4=OBz
(71)   R1=OH, R2=R3=H, R4=OAc
ii, iiii, iii
Reagents and conditions: i) 1 eq. t-BuOK, DMF, RT ii) 3 eq. t-BuOK, DMF, RT iii) 1 eq.
corresponding halide, RT
Scheme 42. Synthesis of regioselectively protected isoflavones
Introduction of the Bn group in total synthesis was also studied. In our experience, the Bn
group cannot be introduced at the beginning of the isoflavone synthesis when using the
Houben-Hoesch or Friedel-Crafts type approaches, as the reaction conditions in both of
these reaction routes are highly acidic. In a Houben-Hoesch reaction hydrogen chloride is
introduced to the reaction mixture and in a Friedel-Crafts acylation hydrogen fluoride is
formed during the reaction. Partial cleavage is observed in both of these reactions,
regardless of the position of the Bn group (7-O or 4´-O).
Transesterification was also employed in the synthesis of Bz protected isoflavones. This
known phenomenon (see Chapter 1.4.5.2) was first observed in the synthesis of isoflavone
4´-O-glucosides by a two-phase reaction. It was noticed that the use of Bz protection in the
position 7-O in the synthesis of 4´-O-glucoside resulted in the transition of the Bz group to
position 4´-O and the glycosidation to position 7-O. This observation was confirmed by
conducting the reaction for only 7-O-Bz-daidzein (97) under the same two-phase
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conditions. The result was that only 4´-O-Bz-daidzein (144) and daidzein (4) could be
isolated. It seems that the transesterification is rapidly taking place since no 4´-O
glycosidated compounds were detected in the glycosidation reaction. Further studies were
conducted with different bases. By using t-BuOK (1 eq.) as a base in DMF, 7-O-Bz-
daidzein (97) could be transformed into 4´-O-Bz-daidzein (144) in 40% yield. Despite the
anhydrous conditions, a partial hydrolysis was obtained. Obviously, traces of H2O were
present. The same results were obtained with genistein (5) and glycitein (6). It was also
noted that by using K2CO3 (5 eq.) as a base in DMF, 4´-O-Bz-isoflavones could be
synthesised with moderate yields with BzCl (see Chapter 4) (Scheme 43).
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R1
R2
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O
(4) R1=R2=H
(5) R1=H, R2=OH
(6) R1=OMe, R2=H
(144) R1=R2=H
(102) R1=H, R2=OH
(145) R1=OMe, R2=H
i, ii
Reagents and conditions: i) K2CO3, DMF, RT ii) BzCl, RT
Scheme 43. Synthesis of 4´-O-Bz-isoflavones by using K2CO3
Selective insertion of the protecting groups was achieved succesfully but the deprotection
appeared to be problematic. The ester bonded protecting groups were easily hydrolysed
using KOH in EtOH but the cleavege of the phenolic Bn group by common methods like
Pd/C and H2 or HCOONH4,174 resulted in a partial reduction of the double bond in the C-
ring. This problem was finally overcome using the ‘push and pull’ method, described in
the Chapter 3.4.
3.6.2 SYNTHESIS OF GLYCITEIN CARBOXYMETHYL O-CONJUGATES
As mentioned in the introduction part of this chapter, carboxylic acid derivatives were
needed in two cases, for the development of TR-FIA for glycitein (6) and the synthesis of
isoflavone daunorubicin conjugates.
The glycitein carboxymethyl O-conjugates were synthesised by previously published
methods for daidzein (4) and genistein (5) with slight variations.160 The regioselective
reaction was achieved by controlling the amount of the base and using DMF as a solvent
at room temperature. Both 7 and 4´ O-conjugates (146, 147) were obtained in moderate
yields after the hydrolysis step (see Chapter 4) (Scheme 44). The problematic step in the
synthesis was the purification of the formed carboxymethyl ester conjugates. Due to the
low solubility of glycitein (6), compared to that of daidzein (4) and genistein (5), some
product was repeatedly lost in the purification step (compared to HPLC).
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Reagents and conditions: i) 1 eq. t-BuOK, DMF, RT ii) ethylbromoacetate, RT iii) 3 eq. t-BuOK, RT
 iv) ethylbromoacetate, RT v) COOH, p-toluenesulphonic acid,  reflux
i, ii, v iii, iv, v
(6)
(146) (147)
Scheme 44. Synthesis of glycitein carboxymethyl derivatives
3.6.3 SYNTHESIS OF DAIDZEIN-4´-O-b-GLUCOSIDE
In 1976, daidzein-4´-O-b-glucoside (78) was isolated from Pipthansus nepalensis by Paris
et al.208 Lewis et al. reported in 1998 that they had developed a method for regioselective
synthesis for daidzein and genistein 4´-O-b-glucosides (78, 77).147 In 2001, Boryski et al.
reported that they had noticed that in the spectrum of genistein-4´-O-b-glucoside (77),
published by Lewis et al., the diagnostic signals of the remaining phenolic OH at 4´ (9.60
ppm), and aromatic protons 3´, 5´-H (6.83 ppm), 6-H (6.47 ppm) and 8-H (6.72 ppm)
confirmed a substitution to position 7-O instead of claimed position 4´-O (Table 2).148
There are two publications which report the NMR spectra of isolated genistein-4´-O-b-
glucoside (77).209,210 When the spectrum of the synthesised genistein-4´-O-b-glucoside
(77)147 is compared to the spectrum of isolated genistein-7-O-b-glucoside (2)210, the
spectra are virtually identical (Table 2).
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Table 2. 1H NMR comparison of genistein (5), genistin (2) and sophoricoside (77)
d values in ppm, solvent DMSO-d6
From these observations it was obvious that the synthesis described to genistein-4´-O-b-
glucoside (77)147 in fact yields the corresponding 7-O analogue (2). In 2006, Weis et al.
biosynthesised daidzein-4´-O-b-glucoside (78), which was characterised by 1H NMR.211
Due to the NMR solvent they used (CD3OD), the comparison of the spectrum with the
synthesised analogue is rather complicated (Table 3). To confirm the structure of daidzein-
4´-O-b-glucoside (78), it was decided to synthesise by using a protecting group to obtain
the absolute stereochemistry, in this case b anomer.
Table 3. 1H NMR comparison of daidzein (4) and daizein-4´-O-glucoside (78)
1H daidzein (4) a) (78) synthesised147 a) (78) entsymatic211
b)
(78) a), c)
H-2 8.29 8.43 8.17 8.35
H-5 7.96 8.05 8.06 7.97
H-6 6.93 7.02 6.94 6.94
H-8 6.86 6.96 7.16 6.87
H-2´, 6´ 7.38 7.58 7.49 7.50
H-3´, 5´ 6.80 7.16 6.86 7.08
d values in ppm, a) DMSO-d6, b) CD3OD, c) see chapter 4
The initial approach was first to protect position 7-O of daidzein (4) with Ac and Bz
groups. Glycosidation was attempted with the Koenigs-Knorr method and also with a two-
phase method, described in connection with sulphoglucuronide synthesis (Chapter 3.4).
Both of these glycosidation methods resulted in transesterification of Ac and Bz groups.
The protecting group was changed to Bn, since it was known to be stable under the these
glycosidation conditions (Chapter 3.4). After the successful benzylation of position 7-O,
glycosidation to position 4´-O was performed by the two-phase reaction with 32% yield.
After debenzylation by thioanisole/TFA and ester hydrolysis by KOH in EtOH, the target
compound daidzein-4´-O-b-glucoside (78) was obtained (see Chapter 4) (Scheme 45).
1H genistein (5) genistin (2)
isolated210
genistin (2)
synthesised139
(77)
isolated209
(77)
synthesised147
H-2 8.32 8.34 8.35 8.37 8.43
H-5 12.96 (OH) - 12.93 (OH) 12.90 (OH) 12.94 (OH)
H-6 6.23 6.47 6.55 6.23 6.47
H-8 6.39 6.73 6.79 6.39 6.72
H-2´, 6´ 7.38 7.41 7.44 7.49 7.40
H-3´, 5´ 6.83 6.83 6.91 7.09 6.83
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Reagents and conditions: i) t-BuOK, DMF, RT ii) BnCl. iii) a-acetobromoglucose, K2CO3, Bu4NBr,
CHCl3, H2O, RT iv) thioanisole, TFA, 40 °C v) KOH, EtOH, RT
i, ii
iii
iv
v
(4) (96)
(148)
(149)
(78)
Scheme 45. Synthesis of daidzein-4´-O-b-glucoside (78)
The structure of the compound was verified with 1H and 13C NMR and 2D NMR [HMQC
(1H-13C), HMBC (1H-13C)]. When comparing these spectra (1H and 13C NMR) with the
spectrum of previously synthesised (78),147 it can be seen that the diagnostic signals
correlate (Table 3). However, the synthesis of daidzein-4´-O-b-glucoside (78) described
here gives the absolute conformation including the assignments of the hydroxy groups at
monosaccharide moiety.
3.6.4 SYNTHESIS OF DAIDZEIN-4´-O-Bz-7-O-TRIACETYLGLUCURONIDE
METHYL ESTER
As previously mentioned, the transesterification between the hydroxy groups 7 and 4´ can
be exploited in the synthesis of 7-O-glycosides (Chapter 3.6.1). This phenomenon was
observed during the synthesis of daidzein-4´-O-b-glucoside (78). The Bz protection at
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position 7-O was transferred during the synthesis to position 4´-O and the glycosidation
took place at position 7-O. This observation encouraged us to try this approach in the
synthesis of daidzein-4´-O-Bz-7-O-triacetylglucuronide methyl ester (150), which could
be then hydrolysed to give daizein-7-O-b-glucuronide (8). The synthesis was started from
daidzein (4) by selective benzoylation at the position 7-O (Scheme 46). Glycosidation was
performed by the earlier described two-phase reaction, during which the transesterification
took place. The target molecule (150) was obtained, after purification, in 34% yield (see
Chapter 4).
OHO
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O
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OAc
AcO
AcO
O
O
i, ii
iii, iv
Reagents and conditions: i) t-BuOK, DMF, RT ii) BzCl iii) 1 eq. a-acetobromoglucuronide methyl
ester, K2CO3, Bu4NBr, CHCl3, H2O iv) 1 eq. a-acetobromoglucuronide methyl ester
(4) (97)
(150)
Scheme 46. Synthesis of daidzein-4´-O-Bz-7-O-triacetylglucuronide methyl ester (150)
The main advantages of this approach are the clean reaction and easy purification, since
the formed product is readily soluble in organic halogenated solvents affording liquid
extraction steps, followed by column chromatography and recrystallisation. It has to be
noted that in the situation where the hydroxy group at position 4´ is unprotected and the
protecting groups at glucuronic acid are still present, the molecule is polar making the
purification more complex by column chromatography. In our experience, only
recrystallisation can be used (see Chapter 3.4). As can be seen, protecting groups play an
important role in the synthesis of isoflavone glucosides and glucuronides, regarding both
selectivity and solubility.
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3.6.5 SYNTHESIS OF DAUNORUBICIN CONJUGATE OF BIOCHANIN A
There are few publications concerning the coupling of daunorubicin (111) to estrogen type
of compounds, which might enhance the selectivity of the antitumor agents against tumor
cells or tissues.212,213 The idea is that a carrier molecule which has shown selectivity
towards the desired binding site will target the cytotoxicity of daunorubicin (111)
selectively to the tumors. This carrier type of approach could also be used to overcome the
known multi drug resistance (MDR) problem.
Biochanin A (134) which itself has shown some biological activity in human was chosen
for a carrier molecule. The first option for the linker between biochanin A (134) and
daunorubicin (111) was an alkylamine chain (Scheme 47). The problem, however, was the
cleavage of the phthalimide protection. The use of hydrazine hydrate resulted in a reaction
at the C-ring leading to compound (152) (see Chapter 4) (Scheme 47).
OHO
O
OMe
OO
O
OMe
N
O
O
NH
N
MeO
O OH
OH
OH
OH
Reagents and conditions: i) N-(4-bromobutyl)phthalimide, K2CO3, NaI, acetone, reflux
ii) N2H4.H2O, EtOH, reflux
i
ii
(134)
(151)
(152)
H2N
Scheme 47. Synthetic approach to an alkylamine derivative of biochanin A
This is a known behaviour of isoflavones and benzyl flavones under these reaction
conditions.214,215  The following mechanism is based on the mechanism suggested by
Lévai et al. for 3-benzylchromones (Scheme 48).214
83
RO OH
OH
N
H
N
MeO
ORO
OH O
OMe
H2N NH2
ORO
OH O
OMe
H2N NH2
RO OH
OH O NH
H2N
OMeRO OH
OH
NH
N
MeO
Scheme 48. Proposed mechanism for pyrazole formation by hydrazine hydrate
Hydrolysis of the phthalimido moiety was also studied with NaOH,216 HCl217 and
MeNH2218 without any success. There are different approaches to obtain the amine group,
including the reduction of the nitrile (CN) or nitro (NO2) functionalities.219  However, the
low reactivity of these alkyl halides and the potential reduction of the double bond at C-
ring forced us to consider other approaches. It was decided to use carboxylic acid
functionality at the point of attachment, due to the possibilities of activation procedures
that can be applied.220 The options for the activation of carboxylic acid were: formation of
the acid chloride, use of DCC as an activator or use of mixed anhydride. The formation of
the acid chloride resulted in the chlorination of biochanin A (111) (see Chapter 3.5). The
problem in the DCC activation was that instead of the desired reaction, the O-acyl urea
decomposed to the corresponding amide derivative (Scheme 49). This is a well-known
problem when dealing with poor nucleophiles.221
NH C N
O O
R
NH C N
O
O
R
Scheme 49. Decomposition of O-acyl urea
The mixed anhydride method, using pivaloyl chloride worked successfully giving the
desired product, daunorubicin biochanin A derivative (153) (see Chapter 4) (Scheme 50).
Similar kind of synthesis using mixed anhydride method has been described for the
synthesis of a daunorubicin estrogen conjugate.213 The biological activity of (153) was
tested on MCF7 and Ishikawa cell lines. The compound (153) did not show any activity
on these cell lines. Other potential cell lines will be tested in the future.
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Reagents and conditions: i) ethyl 4-bromo butyrate, K2CO3, KI, acetone, reflux ii) HCOOH, p-toluene-
sulphonic acid, H2O, reflux iii) pivaloyl chloride, Et3N, DMF, -16 °C iv) Et3N, DMF, -16 °C to RT
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Scheme 50. Synthesis of the daunorubicin biochanin A derivative (153)
4. EXPERIMENTAL
4.1 Synthesis of glycitein
4-Methoxy resorcinol (112) was synthesised according to the previously published
procedure.89 4-Hydroxy phenyl acetonitrile (113) (9.2 g, 69.1 mmol), 4-methoxy
resorcinol (112) (8.0 g, 57.1 mmol) and fused ZnCl2 (6.1 g, 45.1 mmol) were dissolved
into dry ether (240 ml). Dry HCl gas, generated from NaCl, HCl and H2SO4, was bubbled
into the solution for 5 hours. After bubbling, the violet reaction mixture was left to room
temperature over night (14 hours). Ether was decanted off and the gummy solid was
washed with dry ether. To hydrolyse the formed ketiminium chloride, 5% HCl (200 ml)
was added and the mixture was refluxed for 8 hours. The formed solution was left in the
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refrigerator over night. The yellow crystals were filtered off and washed with water. The
recrystallisation from EtOH gave 2,4,4´-trihydroxy-5-methoxy deoxybenzoin (115) (8.1 g,
52%) 1H NMR (200 MHz, acetone-d6): d = 3.85 (s, 3H, OMe-5), 4.20 (s, 2H, CH2), 6.36
(s, 1H, H-3), 6.80 (d, 2H, J=8.8 Hz, H-3´, H-5´), 7.19 (d, 2H, J=8.8 Hz, H-2´, H-6´), 7.50
(s, 1H, H-6), 8.25 (s, 1H, OH-4´), 8.89 (s, 1H, OH-4), 12.6 (s, 1H, OH-2).
The cyclisation of (115) was performed as follows. BF3-Et2O (15.8 ml, 124.8 mmol) was
added dropwise to a solution of 2,4,4´-trihydroxy-5-methoxy deoxybenzoin (115) (7.0 g,
25.5 mmol) in dry DMF (70 ml) under argon atmosphere. The temperature was raised to
50 °C and a solution of methanesulphonyl chloride (6.1 ml, 79.4 mmol) in dry DMF (20
ml) was added slowly into the reaction mixture. The resulting mixture was then stirred at
100 °C for 2 hours. It was cooled to room temperature and poured into ice water (800 ml)
and left in the refrigerator over night. The resulting crystals were filtered off and washed
with water. To hydrolyse the partially formylated 7-O position the solid was dissolved into
0.5M NaOH (200 ml) and after stirring for 1 hour at room temperature it was acidified
with conc. HCl. The resulting precipitated solid was filtered off and washed with water.
Recrystallisation from AcOH gave off white solid (6) (6.5 g, 90%). 1H and 13C NMR (I)
4.2 Synthesis of daidzein-4´-O-b-glucoside
7-O-Bn-daizein (96) (115 mg, 0.33 mmol), Bu4N+Br- (129 mg, 0.40 mmol), K2CO3 (230
mg, 1.67 mmol), CHCl3 (10 ml) and water (10 ml) were placed in a round bottomed flask
and the mixture was stirred at room temperature. After obtaining the clear solution (10
min), acetobromo-a-D-glucose (62) (137 mg, 0.33 mmol) was added. After two days
another equivalent (137 mg, 0.33 mmol) of acetobromo-a-D-glucose (62) was added. The
reaction mixture was stirred for a total of seven days. CHCl3 (40 ml) was added and the
separated organic phase was washed with 10% aq. AcOH (2 x 15 ml), water (15 ml), 0.1M
Na2S2O3 (15 ml), water (15 ml), sat. NaHCO3 (2 x 15 ml) and water (2 x 15ml), and dried
with MgSO4. The solvent was removed in vacuo to give a solid (326 mg), which was
purified by MPLC using CH2Cl2 : MeOH (95 : 5) as an eluent. This gave white solid (244
mg) which was recrystallised from EtOH to give daidzein-7-O-Bn-4´-O-
tetraacetylglucoside (148) as white solid (72 mg, 32%) 1H NMR (500 MHz, CDCl3): d =
2.04-2.09 (4 x s, 12H, Ac), 3.88 (m, 1H, H-2´´), 4.18 (d, 1H, J=12.0 Hz, H-6´´), 4.30 (dd,
1H, J=13.0 Hz, 5.0 Hz, H-6´), 5.11 (m, 1H, H-1´´), 5.18 (s, 2H, H-7´´), 5,18 (m, 1H, H-
3´´), 5.30 (m, 1H, H-4´´), 5.32 (m. 1H, H-5´´), 6.94 (d, 1H, J=2.0 Hz, H-8), 7.06 (d, 2H,
J=9.0 Hz, H-3´, H-5´), 7.08 (d, 1H, J=2.5 Hz, H-6), 7.37 (m, 1H, H-4´´´), 7.43 (m, 2H, H-
3´´´, H-5´´´), 7.46 (d, 2H, J=7.0 Hz, H-2´, H-6´), 7.50 (d, 2H, J=9.0 Hz, H-2´´´, H-6´´´),
7.91 (s, 1H, H-2), 8.22 (d, 1H, J=9.0 Hz, H-5); 13C NMR (125 MHz, CDCl3): 20.8 (Ac x
4), 62.1 (C-6´´), 68.5 (C-3´´), 70.7 (C-4´´), 71.3 (C-4´´), 71.3 (C-7´´), 72.3 (C-2´´), 72.9
(C-5´´), 99.4 (C-1´´), 101.4 (C-8), 115.3 (C-6), 117.2 (C-3´, C-5´), 118.7 (C-4a), 124.7 (C-
1´), 127.2 (C-3), 127.7 (C-3´´´, C-5´´´), 128.0 (C-4´´´), 128.6 (C-5), 128.9 (C-2´´´, C-6´´´),
130.4 (C-2´, C-6´), 135.8 (C-1´´´), 152.4 (C-2), 157.0 (C-4´), 158.0 (C-8a), 163.2 (C-7),
169.5 (C=O), 196.5 (C=O), 170.4 (C=O), 170.7 (C=O), 175.8 (C-4).
Debenzylation of (148) was performed as follows. A mixture of daidzein-7-O-Bn-4´-
tetraacetylglucoside (148) (52 mg, 0.08 mmol), thioanisole (0.45 ml, 3.9 mmol) and
CF3COOH (2 ml) was stirred at 40 °C for 2 hours. The solvent was evaporated in vacuo
86
and the product was precipitated from the resulting oil with Et2O/hexane. The formed
solid was filtered off and washed with water. Recrystallisation from EtOH gave daizein-
4´-O-tetra-acetylglucoside (149) as white solid (30 mg, 67%) The purity of the sample was
verified by LC-MS.
Deacetylation of (149). A suspension of daizein-4´-O-tetra-acetylglucoside (149) (30 mg,
0.05 mmol), KOH (2 mg), EtOH (15 ml) and drop of water, was stirred at room
temperature for 5 hours. After completion of the reaction, solvents were evaporated in
vacuo, water (10 ml) was added and the solution was neutralised with 10% HCl. The
precipitated solid was filtered of and washed with water. Recrystallisation from
MeOH/H2O gave daidzein-4´-O-b-D-glucoside (78) as white solid (18 mg, 86%). 1H
NMR (500 MHz, DMSO-d6): d = 3.18 (m, 1H, H-4´´), 3.27 (m, 1H, H-3´´), 3.29 (m, 1H,
H-2´´), 3.35 (m, 1H, H-5´´), 3.48 (m, 1H, H-6´´), 3.70 (m, 1H, H-6´´), 4.55 (s, 1H, OH-
6´´), 4.91 (d, 1H, J=6.5 Hz, H-1´´), 5.00 (d, 1H, J=5.0 Hz, OH-4´´), 5.07 (d, 1H, J=3.5 Hz,
OH-3´´), 5.31 (d, 1H, J=4.0 Hz, OH-2´´), 6.87 (s, 1H, H-8), 6.94 (d, 1H, J=8.0 Hz, H-6),
7.08 (d, 2H, J=8.5 Hz, H-3´, H-5´), 7.50 (d, 2H, J=7.5 Hz, H-2´, H-6´), 7.97 (d, 1H, J=9.0
Hz, H-5), 8.35 (s, 1H, H-2), 10.79 (s, 1H, OH-7) ); 13C NMR (125 MHz, DMSO-d6): 60.7
(C-6´´), 69.7 (C-4´´), 73.2 (C-3´´), 76.6 (C-2´´), 77.0 (C-5´´), 100.4 (C-1´´), 102.1 (C-8),
115.2 (C-6), 116.0 (C-3´, C-5´), 116.6 (C-4a), 123.1 (C-3), 125.5 (C-1´), 127.3 (C-5),
129.9 (C-2´, C-6´), 153.2 (C-2), 157.1 (C-4´), 157.4 (C-8a), 162.5 (C-7), 174.5 (C-4).
4.3 Regioselective synthesis of isoflavone O-derivatives using t-BuOK as a base
General synthesis for 4´-O-isoflavone derivatives
A suspension of isoflavone (300 mg, 1 eq.) and dry t-BuOK (3 eq.) in freshly distilled
DMF (40 ml) was stirred at room temperature under Ar for 2 hours. Freshly distilled
corresponding halide (1.1 eq.) was added and the reaction mixture was stirred overnight
and then poured into water and neutralised with 10% HCl. The precipitated product was
filtered off, washed with water, dried in vacuo and purified with MPLC using CH2Cl2 :
EtOAc (8:2) as an eluent.
The corresponding halides were: AcCl (acetyl protection), BnCl (benzyl protection), BzCl
(benzoyl protection) and ethylbromoacetate (ethoxycarbonylmethylglycitein)
Recrystallisation from EtOH gave 4´-O-ethoxycarbonylmethylglycitein (156) as white
solid (148 mg, 41%) 1H NMR (500 MHz, DMSO-d6): d = 1.21 (t, 3H, J=6.8 Hz, H-4´´),
3.87 (s, 3H, OMe-6), 4.17 (q, 2H, J=7.0Hz, H-3´´), 4.80 (s, 2H, H-1´´), 6.96 (s, 1H, H-8),
6.98 (d, 2H, J=8.5 Hz, H-3´, H-5´), 7.44 (s, 1H, H-5), 7.51 (d, 2H, J=9.0Hz, H-2´, H-6´),
8.34 (s, 1H, H-2), 10.60 (s, 1H, OH-7); 13C NMR (50 MHz, DMSO-d6): 13.7 (C-4´´), 55.5
(C-OMe), 60.3 (C-3´´), 64.3 (C-1´´), 102.5 (C-8), 104.4 (C-5), 113.8 (C-3´, C-5´), 115.9
(C-4a), 122.2 (C-1´), 124.9 (C-3), 129.7 (C-2´, C-6´), 146.6 (C-6), 151.4 (C-8a), 152.6 (C-
2), 152.6 (C-7), 156.9 (C-4´), 168.4 (C-2´´), 173.8 (C-4). HRMS (EI) calculated for:
C20H18O7: 370.1053; found: 370.1068.
Recrystallisation from EtOH gave 4´-O-Ac-daidzein (71) as white solid (150 mg, 43%).
1H NMR (500 MHz, DMSO-d6): d = 2.29 (s, 3H, Ac), 6.89 (d, 1H, J=2.5 Hz, H-8), 6.95
(dd, 1H, J=2.0 Hz, 9.0 Hz, H-6), 7.18 (d, 2H, J=8.5 Hz, H-3´, H-5´), 7.60 (d, 2H, J=9.0
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Hz, H-2´, H-6´), 7.99 (d, 1H, J=9.0 Hz, H-5), 8.42 (s, 1H, H-2), 10.82 (s, 1H, OH-7); 13C
NMR (125 MHz, DMSO-d6): 20.8 (C-Ac), 102.2 (C-8), 115.3 (C-6), 116.6 (C-4a), 121.5
(C-3´, C-5´), 121.8 (C-1´´), 122.8 (C-3), 127.3 (C-5), 130. 0 (C-2´, C-6´), 150.1 (C-4´),
153.9 (C-2), 157.4 (C-8a), 162.7 (C-7), 169.2 (C=O), 174.3 (C-4).
Recrystallisation from EtOH gave 4´-O-Bn-genistein (142) as white solid (240 mg, 60 %).
1H NMR (200 MHz, DMSO-d6): d = 5.16 (s, 2H, H-7´´), 6.24 (d, 1H, J=2.2 Hz, H-6), 6.40
(d, 1H, J=2.2 Hz, H-8), 7.08 (d, 2H, J=8.8 Hz, H-3´, H-5´), 7.33-7.52 (m, 7H, H-2´ ,´ H-
3´ ,´ H-4´´, H-5´ ,´ H-6´´, H-2 ,´ H-6´), 8.38 (s, 1H, H-2), 10.92 (s, 1H, OH-7), 12.89 (s, 1H,
OH-5); 13C NMR (50 MHz, DMSO-d6): 69.2 (C-7´´), 93.7 (C-8), 99.0 (C-6), 104.5 (C-4a),
114.6 (C-3´, C-5´), 122.0 (C-1´), 123.2 (C-3), 127.6 (C-2´ ,´ C-6´´), 127.8 (C-4´´), 128.5
(C-3´ ,´ C-5´´), 130.2 (C-2´, C-6´), 137.0 (C-1´´), 154.4 (C-2), 157.6 (C-4´), 158.2 (C-8a),
162.0 (C-5), 164.3 (C-7), 180.1 (C-4).
Recrystallisation from EtOH gave 4´-O-Bn-glycitein (143) as white solid (178 mg, 45%)
1H NMR (200 MHz, DMSO-d6): d = 3.88 (s, 3H, OMe-6), 5.16 (s, 2H, H-7´´), 6.96 (s, 1H,
H-8), 7.07 (d, 2H, J=8.8 Hz, H-3´, H-5´), 7.33-7.53 (m, 8H, H-2´´, H-3´´, H-4´´, H-5´´, H-
6´ ,´ H-2 ,´ H-6 ,´ H-5), 8.34 (s, 1H, H-2), 10.62 (s, 1H, OH-7); 13C NMR (50 MHz, DMSO-
d6): 55.8 (C-OMe), 69.2 (C-7´´), 102.8 (C-8), 104.7 (C-5), 114.5 (C-3´, C-5´), 116.2 (C-
4a), 122.6 (C-1´), 124.7 (C-3), 127.6 (C-2´ ,´ C-6´´), 127.8 (C-4´´), 128.4 (C-2´, C-6´),
130.1 (C-3´ ,´ C-5´´), 137.1 (C-1´´), 147.0 (C-6), 151.7 (C-8a), 152.9 (C-2, C-7), 158.0 (C-
4´), 174.2 (C-4).
Recrystallisation from EtOH gave 4´-O-Bz-daidzein (144) as white solid (204 mg, 52%)
1H NMR (200 MHz, DMSO-d6): d = 6.91 (d, 1H, J=2.2 Hz, H-8), 6.97 (dd, 1H, J=2.2 Hz,
8.8 Hz, H-6), 7.37 (d, 2H, J=8.8 Hz, H-3´, H-5´), 7.63 (t, 2H, J=7.0 Hz, H-3´´, H-5´´),
7.68 (d, 2H, J=8.6 Hz, H-2´, H-6´), 7.78 (t, 1H, J=7.0 Hz, H-4´´), 8.01 (d, 1H, J=8.6 Hz,
H-5), 8.17 (d, 2H, J=7.0 Hz, H-2´ ,´ H-6´´), 8.48 (s, 1H, H-2), 10.87 (s, 1H, OH-7); 13C
NMR (50 MHz, DMSO-d6): 102.1 (C-8), 115.2(C-6), 116.5 (C-4a), 121.6 (C-3´, C-5´),
122.7 (C-1´), 123.8 (C-3), 127.2 (C-5), 128.9 (C-2 ,´ C-6´), 129.8 (C-3´ ,´ C-5´´), 130.0 (C-
2´ ,´ C-6´´), 134.0 (C-4´´´), 136.0 (C-1´´), 150.1 (C-4´), 153.9 (C-2), 157.4 (C-8a), 162.6
(C-7), 164.5 (C-7´´), 174.3 (C-4).
Recrystallisation from EtOH gave 4´-O-Bz-genistein (102) as white solid (224 mg, 54%)
1H NMR (500 MHz, DMSO-d6): d = 6.26 (d, 1H, J=1.5 Hz, H-6), 6.43 (d, 1H, J=2.0 Hz,
H-8), 7.38 (d, 2H, J=8.5 Hz, H-3´, H-5´), 7.63 (t, 2H, J=8.0 Hz, H-3´´, H-5´´), 7.68 (d, 2H,
J=9.0 Hz, H-2´, H-6´), 7.77 (t, 1H, J=7.5 Hz, H-4´´), 8.16 (d, 2H, J=8.0 Hz, H-2´´, H-6´´),
8.50 (s, 1H, H-2), 10.92 (s, 1H, OH-7), 12.86 (s, 1H, OH-5); 13C NMR (125 MHz,
DMSO-d6): 93.8 (C-8), 99.1 (C-6), 104.4 (C-4a), 121.5 (C-1´), 121.5 (C-3), 121.7 (C-3´,
C-5´), 128.6 (C-1´´), 128.9 (C-3´ ,´ C-5´´), 129.8 (C-2´ ,´ C-6´´), 130.1 (C-2´, C-6´), 134.0
(C-4´´), 150.4 (C-4´), 155.1 (C-2), 157.6 (C-8a), 162.0 (C-5), 164.5 (C-7), 164.6 (C-7´´),
179.8 (C-4).
Recrystallisation from EtOH gave 4´-O-Bz-glycitein (145) as white solid (166 mg, 42%)
1H NMR (500 MHz, DMSO-d6): d = 3.90 (s, 3H, OMe-6), 6.98 (s, 1H, H-8), 7.36 (d, 2H,
J=9.0 Hz, H-3 ,´ H-5´), 7.48 (s, 1H, H-5), 7.63 (t, 2H, J=8.0 Hz, H-3´´, H-5´´), 7.69 (d, 2H,
J=9.0 Hz, H-2´, H-6´), 7.76 (t, 1H, J=7.0 Hz, H-4´´), 8.16 (d, 2H, J=7.5 Hz, H-2´´, H-6´´),
8.44 (s, 1H, H-2), 10.55 (s, 1H, OH-7); 13C NMR (125 MHz, DMSO-d6): 55.8 (C-OMe),
102.8 (C-8), 104.8 (C-5), 116.2 (C-4a), 121.5 (C-3´, C-5´), 122.2 (C-1´, C-3), 128.8 (C-
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3´ ,´ C-5´´), 129.7 (C-2´ ,´ C-6´´), 129.9 (C-2´, C-6´), 130.0 (C-1´´), 133.9 (C-4´´), 147.0
(C-6), 150.1 (C-4´), 151.7 (C-8a), 153.0 (C-7), 153.4 (C-2), 164.5 (C-7´´), 173.9 (C-4).
General synthesis of 7-O-isoflavone derivatives
A suspension of isoflavone (300 mg, 1 eq.) and dry t-BuOK (1 eq.) in freshly distilled
DMF (40 ml) was stirred at room temperature under Ar for 2 hours. Freshly distilled
corresponding halide (1.1 eq.) was added and the reaction mixture was stirred overnight
and then poured into water and neutralised with 10% HCl. The precipitated product was
filtered off, washed with water, dried in vacuo and purified with MPLC using CH2Cl2 :
EtOAc (8:2) as an eluent.
The corresponding halides were: AcCl (acetyl protection), BnCl (benzyl protection), BzCl
(benzoyl protection), ethylbromoacetate (ethoxycarbonylmethylglycitein) and ethyl-4-
bromobutyrate (ethoxycarbonylpropylgenistein)
Recrystallisation from EtOH gave 7-O-ethoxycarbonylmethylglycitein (157) as white
solid (242 mg, 67%) 1H NMR (200 MHz, DMSO-d6): d = 1.23 (t, 3H, J=7.0 Hz, H-4´´),
3.90 (s, 3H, OMe-6), 4.20 (q, 2H, J=7.0 Hz, H-3´´), 5.01 (s, 2H, H-1´´), 6.82 (d, 2H, J=8.8
Hz, H-3´, H-5´), 7.20 (s, 1H, H-8), 7.41 (d, 2H, J=8.4 Hz, H-2´, H-6´), 7.47 (s, 1H, H-5),
8.37 (s, 1H, H-2), 9.55 (s, 1H, OH-4´); 13C NMR (50 MHz, DMSO-d6): 13.7 (C-4´´), 55.5
(C-MeO), 60.5 (C-3´´), 65.0 (C-1´´), 101.2 (C-8), 104.3 (C-5), 114.6 (C-3´, C-5´), 117.2
(C-4a), 122.2 (C-1´), 122.8 (C-3), 129.7 (C-2´, C-6´), 147.0 (C-6), 150.9 (C-8a), 151.9 (C-
2), 152.6 (C-7), 156.8 (C-4´), 167.5 (C-2´´), 173.9 (C-4). HRMS (EI) calculated for:
C20H18O7: 370.1053; found: 370.1064.
Recrystallisation from EtOH gave 7-O-ethoxycarbonylpropylgenistein (158) as white
solid (213 mg, 50%) 1H NMR (500 MHz, acetone-d6): d = 1.23 (t, 3H, J=6.5 Hz, H-6´´),
2.11 (qv, 2H, J=7.0 Hz, H-2´´), 2.52 (t, 2H, J=7.0 Hz, H-3´´´), 4.12 (q, 2H, J=7.5 Hz, H-
5´´), 4.19 (t, 2H, J=6.5 Hz, H-1´´), 6.36 (s, 1H, H-6), 6.55 (s, 1H, H-8), 6.91 (d, 2H, J=8.5
Hz, H-3´, H-5´), 7.46 (d, 2H, J=8.5 Hz, H-2´, H-6´), 8.20 (s, 1H, H-2), 8.48 (s, 1H, OH-
4´), 12.99 (s, 1H, OH-5); 13C NMR (125 MHz, acetone-d6): 14.5 (C-6´´), 25.2 (C-2´´),
31.0 (C-3´´), 60.7 (C-5´´), 68.5 (C-1´´), 93.4 (C-8), 99.2 (C-6), 106.8 (C-4a), 116.0 (C-3´,
C-5´), 123.0 (C-3), 124.3 (C-1´), 131.2 (C-2´, C-6´), 154.6 (C-2), 158.5 (C-8a), 158.9 (C-
4), 163.2 (C-5), 165.9 (C-7), 173.2 (C-4´´), 181.8 (C-4).
Recrystallisation from EtOH gave 7-O-Ac-daidzein (141) as white solid (203 mg, 58%).
1H NMR (500 MHz, DMSO-d6): d = 2.33 (s, 3H, Ac-7), 6.83 (d, 2H, J=9.0 HZ, H-3´, H-
5´), 7.30 (dd, 1H, J=9.0 Hz, 2.0 Hz, H-6), 7.42 (d, 2H, J=9.0 Hz, H-2´, H-6´), 7.54 (d, 1H,
J=2.5 Hz, H.8), 8.16 (d, 1H, J=8.0 Hz, H.5), 8.44 (s, 1H, H-2), 9.56 (s, 1H, OH-4´); 13C
NMR (125 MHz, DMSO-d6): 20.9 (C-2´´), 111.4 (C-8), 115.0 (C-3´, C-5´), 120.0 (C-6),
121.6 (C-1´), 122.0 (C-4a), 124.0 (C-3), 126.9 (C-5), 130.1 (C-2 ,´ C-6´), 153.8 (C-2),
154.3 (C-7), 156.0 (C-8a), 157.4 (C-4´), 168.6 (C-1´´), 174.8 (C-4).
Recrystallisation from EtOH gave 7-O-Bn-daidzein (96) as white solid (268 mg, 66 %).
1H NMR (200 MHz, DMSO-d6): d = 5.27 (s, 2H, H-7´´), 6.82 (d, 2H, J=8.8 Hz, H-3´, H-
5´), 7.15 (dd, 1H, J=2.6 Hz, 9.2 Hz, H.6), 7.25 (d, 1H, J=2.2 Hz, H-8), 7.38-7.52 (m, 7H,
H-2´´, H-3´´, H-4´ ,´ H-5´´, H-6´ ,´ H-2´, H-6´), 8.04 (d, 1H, J=9.2 Hz, H-5), 8.37 (s, 1H, H-
2), 9.56 (s, 1H, OH-4´); 13C NMR (50 MHz, DMSO-d6): 70.0 (C-7´´), 101.5 (C-8), 114.9
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(C-3´, C-5´), 115.1 (C-6), 117.7 (C-4a), 122.3 (C-1´), 123.6 (C-3), 126.9 (C-5), 127.9 (C-
2´ ,´ C-6´´), 128.1 (C-4´´), 128.5 (C-3´ ,´ C-5´´), 130.0 (C-2´, C-6´), 136.0 (C-1´´), 153.1
(C-2), 157.2 (C-4´, C-8a), 162.5 (C-7), 174.6 (C-4).
Recrystallisation from EtOH gave 7-O-Bn-genistein (95) as white solid (256 mg, 64 %).
1H NMR (200 MHz, DMSO-d6): d = 5.24 (s, 2H, H-7´´), 6.50 (d, 1H, J=2.2 Hz, H-6), 6.75
(d, 1H, J=2.2 Hz, H-8), 6.83 (d, 2H, J=8.8 Hz, H-3´, H-5´), 7.35-7.50 (m, 7H, H-2´ ,´ H-
3´ ,´ H-4´´, H-5´ ,´ H-6´´, H-2´, H-6´), 8.41 (s, 1H, H-2), 9.62 (s, 1H, OH-4´), 12.92 (s, 1H,
OH-5); 13C NMR (50 MHz, DMSO-d6): 69.9 (C-7´´), 93.2 (C-8), 98.6 (C-6), 105.4 (C-4a),
127.8 (C-2´ ,´ C-6´´), 128.1 (C-4´´), 126.5 (C-3´ ,´ C-5´´), 130.1 (C-2´, C-6´), 136.0 (C-1´´),
154.4 (C-2), 157.4 (C-4´, C-8a), 161.7 (C-5), 164.1 (C-7), 180.3 (C-4).
Recrystallisation from EtOH gave 7-O-Bn-glycitein (139) as white solid (264 mg, 67%)
1H NMR (200 MHz, DMSO-d6): d = 3.87 (s, 3H, OMe-6), 5.27 (s, 2H, H-7´´), 6.82 (d,
2H, J=8.8 Hz, H-3´, H-5´), 7.33 (s, 1H, H-8), 7.37-7.52 (m, 8H, H-2´ ,´ H-3´´, H-4´ ,´ H-
5´ ,´ H-6´ ,´ H-2´, H-6´, H-5), 8.37 (s, 1H, H-2), 9.55 (s, 1H, OH-4´); 13C NMR (50 MHz,
DMSO-d6): 55.7 (C-OMe), 70.4 (C-7´´), 101.4 (C-8), 104.2 (C-5), 114.9 (C-3´, C-5´),
117.0 (C-4a), 122.5 (C-1´), 123.1 (C-3), 128.1 (C-2´ ,´ C-6´´), 128.1 (C-4´´), 128.5 (C-3´ ,´
C-5´´), 130.0 (C-2´, C-6´), 135.9 (C-1´´), 147.5 (C-6), 151.4 (C-8a), 152.7 (C-2), 153.0
(C-7), 157.1 (C-4´), 174.2 (C-4).
Recrystallisation from EtOH gave 7-O-Bz-daidzein (97) as white solid (257 mg, 61%) 1H
NMR (300 MHz, DMSO-d6): d = 6.84 (d, 2H, J=8.7 Hz, H-3´, H-5´), 7.44 (d, 2H, J=8.4
Hz, H-2´, H-6´), 7.48 (dd, 1H, J=1.8 Hz, 8.7 Hz, H-6), 7.64 (t, 2H, J=8.1 Hz, H-3´´, H-
5´´), 7.76 (d, 1H, J=2.0 Hz, H-8), 7.79 (t, 1H, J=7.2 Hz, H-4´´), 8.19 (d, 2H, J=7.2 Hz, H-
2´ ,´ H-6´´), 8.23 (d, 1H, J=9.0 Hz, H-5), 8.48 (s, 1H, H-2), 9.57 (s, 1H, OH-4´); 13C NMR
(75 MHz, DMSO-d6): 111.7 (C-8), 115.0 (C-3´, C-5´), 120.1 (C-6), 121.8 (C-1´), 122.0
(C-4a), 124.0 (C-3), 127.0 (C-5), 128.4 (C-1´´), 129.0 (C-3´ ,´ C-5´´), 130.0 (C-2´, C-6´),
130.1 (C-2´ ,´ C-6´´), 134.4 (C-4´´), 153.8 (C-2), 154.5 (C-7), 156.1 (C-8a), 157.4 (C-4´),
164.0 (C-7´´), 174.8 (C-4).
Recrystallisation from EtOH gave 7-O-Bz-genistein (98) as white solid (220 mg, 53%)
1H NMR (500 MHz, DMSO-d6): d = 6.85 (d, 2H, J=8.0 Hz, H-3´, H-5´), 6.87 (d, 1H,
J=2.5 Hz, H-6), 7.19 (d, 1H, J=2.0 Hz, H.8), 7.43 (d, 2H, J=9.0 Hz, H-2´, H-6´), 7.63 (t,
2H, J=7.5 Hz, H-3´ ,´ H-5´´), 7.78 (t, 1H, J=7.5 Hz, H-4´´), 8.15 (d, 2H, J=8.0 Hz, H-2´´,
H-6´´), 8.53 (s, 1H, H-2), 9.63 (s, 1H, OH-4´). 13.00 (s, 1H, OH-5); 13C NMR (125 MHz,
DMSO-d6): 101.5 (C-8), 105.4 (C-6), 108.9 (C-4a), 115.1 (C-3´, C-5´), 120.8 (C-1´),
123.0 (C-3), 128.4 (C-1´´), 129.0 (C-3´ ,´ C-5´´), 130.0 (C-2´ ,´ C-6´´), 130.2 (C-2´, C-6´),
134.3 (C-4´´), 155.2 (C-2), 155.9 (C-7), 156.4 (C-8a), 157.6 (C-4´), 161.4 (C-5), 163.7 (C-
7´´), 181.0 (C-4).
Recrystallisation from EtOH gave 7-O-Bz-glycitein (140) as white solid (209 mg, 51%)
1H NMR (500 MHz, DMSO-d6): d = 3.89 (s, 3H, OMe-6), 6.83 (d, 2H, J=8.0 Hz, H-3 ,´ H-
5´), 7.42 (d, 2H, J=8.0 Hz, H-2´, H-6´), 7.63 (t, 2H, J=8.0 Hz, H-3´ ,´ H-5´´), 7.68 (s, 1H,
H-5), 7.78 (t, 1H, J=7.0 Hz, H-4´´), 7.80 (s, 1H, H-8), 8.15 (d, 2H, J=8.0 Hz, H-2´´, H-
6´´), 8.45 (s, 1H, H-2), 9.55 (s, 1H, OH-4´); 13C NMR (125 MHz, DMSO-d6): 56.4 (OMe-
6), 106.0 (C-5), 113.5 (C-8), 115.0 (C-3´, C-5´), 122.3 (C-4a), 122.4 (C-3), 123.3 (C-1´),
128.0 (C-4´´), 129.1 (C-2´, C-6´), 130.0 (C-3´ ,´ C-5´´), 130.1 (C-2´ ,´ C-6´´), 134.4 (C-1´´),
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144.4 (C-7), 149.3 (C-6), 150.0 (C-8a), 153.7 (C-2), 157.3 (C-4´), 163.5 (C-7´´), 174.5 (C-
4).
Hydrolysis of esters to acids
Corresponding isoflavone carboxylic acid ester (100 mg), HCOOH (6 ml), water (0.1 ml)
and p-toluenesulphonic acid (catalytic amount) were refluxed for 12 hours. After cooling,
water (40 ml) was added and the formed suspension was kept at +2°C overnight. Formed
crystals were filtered off and washed with water.
Recrystallisation from MeOH/H2O gave 7-O-carboxylmethylglycitein (146) as white solid
(83 mg, 90%). 1H NMR (500 MHz, DMSO-d6): d = 3.89 (s, 3H, OMe-6), 4.91 (s, 2H, H-
1´´), 6.81 (d, 2H, J=8.50 Hz, H-3´, H-5´), 7.15 (s, 1H, H-8), 7.40 (d, 2H, J=8.50 Hz, H-2´,
H-6´), 7.47 (s, 1H, H-5), 8.36 (s, 1H, H-2), 9.54 (s, 1H, OH-4´); 13C NMR (50 MHz,
DMSO-d6):55.5 (C-OMe), 64.8 (C-1´´), 101.0 (C-8), 104.2 (C-5), 114.6 (C-3´, C-5´),
117.0 (C-4a), 122.2 (C-1´), 122.8 (C-3), 129.7 (C-2´, C-6´), 147.0 (C-6), 150.9 (C-8a),
152.1 (C-2), 152.5 (C-7), 169.0 (C-2´´), 173.9 (C-4). HRMS (EI) calculated for: C18H14O7:
342.0740; found: 342.0749.
Recrystallisation from MeOH/H2O gave 4´-O-carboxylmethylglycitein (147) as white
solid (84 mg, 91%).1H NMR (500 MHz, DMSO-d6): d = 3.89 (s, 3H, OMe-6), 4.72 (s, 2H,
H-1´´), 6.94 (s, 1H, H-8), 6.95 (d, 2H, J=10.0 Hz, H-3´, H-5´), 7.43 (s, 1H, H-5), 7.49 (d,
2H, J=9.0 Hz, H-2´, H-6´), 8.32 (s, 1H, H-2), 10.60 (s, 1H, OH-7); 13C NMR (50 MHz,
DMSO-d6): 55.7 (C-OMe), 64.3 (C-1´´), 102.8 (C-8), 104.6 (C-5), 114.0 (C-3´, C-5´),
116.1 (C-4a), 122.5 (C-1´), 124.9 (C-3), 129.9 (C-2´, C-6´), 146.9 (C-6), 151.6 (C-8a),
152.8 (C-7), 152.8 (C-2), 157.3 (C-4´), 170.1(C-2´´), 174.1 (C-4). HRMS (EI) calculated
for: C18H14O7: 342.0740; found: 342.0724.
Recrystallisation from EtOH gave 7-O-carboxylpropylgenistein (159) as white solid (79
mg, 85%). 1H NMR (500 MHz, DMSO-d6): d = 1.96 (qv, 2H, J=7.0 Hz, H-2´´), 2.40 (t,
2H, J=7.5 Hz, H-3´´´), 4.12 (t, 2H, J=6.5 Hz, H-1´´), 6.40 (s, 1H, H-6), 6.65 (s, 1H, H-8),
6.83 (d, 2H, J=8.5 Hz, H-3´, H-5´), 7.39 (d, 2H, J=8.5 Hz, H-2 ,´ H-6´), 8.40 (s, 1H, H-2),
9.59 (s, 1H, OH-4´), 12.16 (s, 1H, OH-4´´), 12.94 (s, 1H, OH-5); 13C NMR (125 MHz,
DMSO-d6): 23.9 (C-2´´), 29.9 (C-3´´), 67.6 (C-1´´), 92.8 (C-8), 98.4 (C-6), 105.4 (C-4a),
115.1 (C-3´, C-5´), 121.0 (C-3), 122.5 (C-1´), 130.1 (C-2´, C-6´), 154.4 (C-2), 157.5 (C-
8a), 161.8 (C-4), 164.4 (C-5), 164.4 (C-7), 174.0 (C-4´´), 180.4 (C-4).
4.4 Synthesis of 4´-O-Benzoyl-isoflavones by using K2CO3 as a base.
General synthesis of 4´-O-Bz-isoflavones
A suspension of isoflavone (100 mg, 1 eq.) and fused K2CO3 (5 eq.) in freshly distilled
DMF (25 ml) were stirred at room temperature under Ar for 2 hours. Freshly distilled
BzCl (1 eq.) was added and the reaction mixture was stirred overnight and then poured
into water and neutralised with 10% HCl. The precipitated product was filtered off and
washed with water, dried in vacuo and purified with MPLC using CH2Cl2 : EtOAc (8:2) as
an eluent.
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Recrystallisation from EtOH gave 4´-O-Bz-daizein (144) as white solid (69 mg, 49%).
Recrystallisation from EtOH gave 4´-O-Bz-genistein (102) as white solid (93 mg, 67%).
Recrystallisation from EtOH gave 4´-O-Bz-glycitein (145) as white solid (46mg, 35%).
4.5 Synthesis of 7-O-triacetylglucuronic acid methyl ester 4´-O-Benzoyl-daidzein
7-O-Bz-daizein (97) (100 mg, 0.28 mmol), Bu4N+Br- (108 mg, 0.34 mmol), K2CO3 (193
mg, 1.40 mmol), CHCl3 (8 ml) and water (8 ml) were placed in round bottomed flask and
the mixture was stirred at room temperature. After obtaining the clear solution (10 min),
acetobromo-a-D-glucuronic acid methyl ester (70) (111 mg, 0.28 mmol) was added. After
two days another equivalent (111 mg, 0.28 mmol) of acetobromo-a-D-glucuronic acid
methyl ester (70) was added. The reaction mixture was stirred for a total of seven days.
CHCl3 (40 ml) was added and the separated organic phase was washed with 10% aq.
AcOH (2 x 15 ml), water (15 ml), 0.1M Na2S2O3 (15 ml), water (15 ml), sat. NaHCO3 (2 x
15 ml) and water (2 x 15ml), and dried with MgSO4. The solvent was removed in vacuo to
give a solid (288 mg), which was purified by MPLC using CH2Cl2 : MeOH (95:5) as an
eluent. This gave white solid (172 mg) which was recrystallised from EtOH to give 4´-O-
Bz-7-O-triacetylglucuronic acid methyl ester daidzein (150) as white solid (64 mg, 34%)
1H NMR (500 MHz, CDCl3): d = 2.06-2.08 (3 x s, 9H, Ac), 3.74 (s, 3H, H-7´´), 4.29 (d,
1H, J=9.0 Hz, H-5´´), 5.34 (m, 1H, H-1´´), 5.34 (m, 1H, H-2´´), 5.40 (m, 1H, H-3´´), 5.40
(m, 1H, H-4´´), 7.06 (bs, 1H, H.8), 7.08 (d, 1H, J=2.5 Hz, H-8), 7.30 (d, 2H, J=8.5 Hz, H-
3´, H-5´), 7.52 (t, 2H, J=7.5 Hz, H-3´ ,´ H-5´´), 7.63 (d, 2H, J=8.5 Hz, H-2´, H-6´), 7.64
(m, 1H, H-4´´´), 8.00 (s, 1H, H-2), 8.22 (d, 2H, J=8.0 Hz, H-2´´´, H-6´´´), 8.26 (d, 1H,
J=8.0 Hz, H-5); 13C NMR (125 MHz, CDCl3): 20.6 (3 x Ac), 53.1 (C-7´´), 68.9 (C-4´´),
71.0 (C-2´´), 71.6 (C-3´´), 72.8 (C-5´´), 98.4 (C-1´´), 104.5 (C-8), 115.5 (C-6), 120.4 (C-
4a), 121.8 (C-3´, C-5´), 124.8 (C-3), 128.3 (C-5), 128.6 (C-3´´´, C-5´´´), 129.4 (C-1´´),
129.6 (C-4´´), 130.1 (C-2´, C-6´), 130.2 (C-2´´´, C-6´´´), 133.7 (C-4´´´), 151.1 (C-4´),
153.0 (C-2), 157.4 (C-7), 165.1 (C-7´´´), 166.7 (C-6´´), 169.1 (C=O), 169.3 (C=O), 170.0
(C=O), 175.4 (C-4).
4.6 Synthesis of biochanin A 7-O-conjugates
4.6.1 7-O-ethoxycarbonylpropylbiochanin A
Biochanin A (134) (500 mg, 1.76 mmol), K2CO3 (1.3 g, 8.80 mmol), KI (10 mg) and
acetone (50 ml) were placed in a round bottomed flask. Freshly distilled ethyl-4-
bromobutyrate (0.38 ml, 2.64 mmol) was added and the mixture was refluxed for 12
hours. After cooling to room temperature the solvent was removed in vacuo, water (100
ml) was added, neutralization with 10% HCl gave a solid which was filtered off, washed
with water, dried in vacuo and purified with MPLC using CH2Cl2 : EtOAc (8:2) as an
eluent. Recrystallisation from EtOH gave 7-O-ethylcarbonylpropylbiochanin A (160) as
pale yellow crystals (391 mg, 56%) 1H NMR (500 MHz, DMSO-d6): d = 1.19 (t, 3H,
J=7.0 Hz, H-6´´), 1.99 (qv,  2H, J=6.5 Hz, H-2´´), 2.47 (t, 2H, J=7.5 Hz, H-3´´), 3.79 (s,
3H, OMe-4´), 4.09 (m, 2H, H-5´´), 4.12 (m, 2H, H-1´´), 6.40 (s, 1H, H-6), 6.65 (s, 1H, H-
8), 7.01 (d, 2H, J=8.0 Hz, H-3´, H-5´), 7.52 (d, 2H, J=8.5 Hz, H-2´, H-6´), 8.44 (s, 1H, H-
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2), 12.91 (s, 1H, OH-5); 13C NMR (125 MHz, DMSO-d6): 14.1 (C-6´´), 23.9 (C-2´´), 30.0
(C-3´´), 55.2 (OMe-4´), 59.9 (C-5´´), 67.5 (C-1´´), 92.4 (C-8), 98.4 (C-6), 105.4 (C-4a),
113.7 (C-3´, C-5´), 122.2 (C-3), 122.7 (C-1´), 130.1 (C-2´, C-6´), 154.7 (C-2), 157.5 (C-
8a), 159.2 (C-4´), 161.7 (C-5), 164.4 (C-7), 172.4 (C-4´´), 180.3 (C-4).
The hydrolysis of 7-O-ethylcarbonylpropylbiochanin A (160) (300 mg) was performed as
previously described in procedure 4.3. Recrystallisation from EtOH gave 7-O-
carboxypropylbiochanin A (154) as white solid (250 mg, 90%). 1H NMR (500 MHz,
DMSO-d6): d = 1.97 (qv, 2H, J=6.5 Hz, H-2´´), 2.40 (t, 2H, J=7.0 Hz, H.3´´), 3.79 (s, 3H,
OMe-4´), 4.12 (t, 2H, J=6.5 Hz, H-1´´), 6.41 (d, 1H, J=2.5 Hz, H-6), 6.66 (d, 1H, J=2.5
Hz, H-8), 7.01 (d, 2H, J=9.0 Hz, H-3´, H-5´), 7.52 (d, 2H, J=8.5 Hz, H-2 ,´ H-6´), 8.44 (s,
1H, H-2), 12.91 (s, 1H, OH-5); 13C NMR (125 MHz, DMSO-d6): 23.8 (C-2´´), 29.9 (C-
3´´), 55.1 (C-OMe), 67.5 (C-1´´), 92.8 (C-8), 98.3 (C-6), 105.3 (C-4a), 113.6 (C3´, C-5´),
122.1 (C-3), 122.7 (C-1´), 130.1 (C-2´, C-6´), 154.6 (C-2), 157.4 (C-8a), 159.1 (C-4´),
161.7 (C-5), 164.4 (C-7), 173.9 (C-4´´), 180.2 (C-4).
4.6.2 7-O-(Phthalimide-N-)butylbiochanin A
Biochanin A (134) (500 mg, 1.76 mmol), K2CO3 (1.2 g, 8.79 mmol), NaI (10 mg) were
placed in a round bottomed flask. Acetone (40 ml) was added and formed suspension
warmed to reflux. N-(4-bromobutyl)phthalimide (546 mg, 1.93 mmol) was dissolved into
acetone (10 ml) and added to the refluxing mixture. After the completion of the reaction,
the solution was left to cool down and the solvent was evaporated in vacuo, water (100
ml) was added and the solution acidified with 10% HCl. The formed precipitate was
filtered, washed with water, dried in vacuo and purified with MPLC using CH2Cl2 :
EtOAc (8:2) as an eluent. Recrystallisation from acetone gave off white solid (151) (486
mg, 57%). 1H NMR (500 MHz, CDCl3): d = 1.88 (m, 4H, H-2´´, H-3´´), 3.78 (t, 1H, J=6.5
Hz, H-4´´), 3.84 (s, 3H, OMe-4´), 4.06 (t, 1H, J=6.0 Hz, H-1´´), 6.34 (d, 1H, J=2.0 Hz, H-
6), 6.37 (d, 1H, J=2.0 Hz, H-8), 6.97 (d, 2H, J=8.5 Hz, H-3 ,´ H-5´), 7.45 (d, 2H, J=9.0 Hz,
H-2´, H-6´), 7.11 (m, 2H, H-9´ ,´ H-10´´), 7.84 (m, 2H, H-8´ ,´ H-11´´), 7.85 (s, 1H, H-2),
12.81 (s, 1H, OH-5); 13C NMR (125 MHz, CDCl3): 25.2 (C-3´´), 26.3 (C-2´´), 37.5 (C-
4´´), 55.4 (OMe-4´), 67.8 (C-1´´), 92.9 (C-8), 98.6 (C-6), 106.2 (C-4a), 114.1 (C-3´, C-5´),
123.0 (C-1´), 123.3 (C-8´ ,´ C-11´´), 123.6 (C-3), 130.1 (C-2´, C-6´), 132.1 (C-7´ ,´ C-12´´),
134.0 (C-9´ ,´ C-10´´), 152.6 (C-2), 157.9 (C-4´), 159.8 (C-8a), 162.7 (C-5), 164.8 (C-7),
168.4 (C-6´ ,´ C-12´´), 180.8 (C-4).
4.6.3 Pyrazole from 7-O-(Phthalimide-N-)butylbiochanin A
7-O-(Phthalimide-N-)butylbiochanin A (151) (358 mg, 1eq.) and hydrazine hydrate (0.14
ml, 4 eq.) in EtOH (16 ml) were refluxed for 2 hours. After cooling, the solvents were
evaporated in vacuo. Recrystallisation from MeOH/Et2O gave white solid (152) (260 mg,
100%). 1H NMR (500 MHz, DMSO-d6): d = 1.75 (bs, 4H, H-2´ ,´´ H-3´´´), 2.83 (bs, 2H,
H-4´´´), 3.71 (s, 3H, MeO-4´´), 3.89 (bs, 2H, H-1´´´), 6.08 (3, 2H, H-3´, H-5´), 6.85 (d,
2H, J=6.5 Hz, H-3´ ,´ H-5´´), 7.29 (d, 2H, J=6.5 Hz, H-2´ ,´ H-6´´), 8.39 (s, 1H, H-5); 13C
NMR (125 MHz, DMSO-d6):23.9 (C-3´´´), 25.7 (C-2´´´), 38.5 (C-4´´´), 55.0 (OMe-4´´),
66.6 (C-1´´´), 93.1 (C-3´, C-5´), 95.8 (C-1´), 113.9 (C-3´ ,´ C-5´´), 121.0 (C-4), 124.2 (C-
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1´´), 127.3 (C-2´ ,´ C-6´´), 132.3 (C-5), 136.1 (C-3), 157.9 (C-2´, C-6´), 158.1 (C-4´´),
191.0 (C-4´).
4.7 Synthesis of daunorubicin biochanin A conjugate
Et3N (19 ml, 0.14 mmol) was added to a solution of 7-O-carboxypropylbiochanin A (154)
(50 mg, 0.14 mmol) in dry DMF (5 ml) under Ar atmosphere at –16 °C. Pivaloyl chloride
(17 ml, 0.14 mmol) was added and the resulting mixture was stirred for 30 min, after
which daunorubicin (111) (70 mg, 0.14 mmol) and Et3N (19 ml, 0.14 mmol) in dry DMF
(5 ml) were added. The reaction mixture was allowed to warm to room temperature over
night (12 h) and poured into water (100 ml). The aqueous layer was extracted with CH2Cl2
(4 x 20 ml), the combined organic layers were washed with 3% NaHCO3 (3 x 20 ml), sat.
NaCl (20 ml) and water (2 x 20 ml). The organic phase was dried with MgSO4, filtrated
and the solvent was evaporated in vacuo. After purification with MPLC using CH2Cl2 :
MeOH (95:5) as an eluent, the solid was recrystallised from EtOH/CH2Cl2/hexane to a
give bright red solid (153) (45 mg, 38%). 1H NMR (500 MHz, DMSO-d6): d =1.14 (d, 3H,
J=6.5 Hz, H-6´), 1.46 (m, 1H, H-2´), 1.87 (m, 1H, H-2´), 1.89, (m, 2H, H-2´´´´), 2.09 (m,
1H, H-8), 2.23 (m, 2H, H-3´´´´), 2.67 (s, 3H, H-14), 2.93 (s, 2H, H-10), 3.42 (s, 1H, H-4´),
3.79 (s, 3H, OMe-4), 3.93 (s, 3H, OMe-4´´´), 4.02 (m, 2H, H-1´´´´), 4.02 (m, 1H, H-3´),
4.19 (m, 2H, H-5´), 4.73 (d, 1H, J=5.5 Hz, OH-4´), 4.92 (s, 2H, H-7), 5.23 (s, 1H, H-1´),
5.51 (s, 1H, OH-9), 6.31 (s, 1H, H-6´´), 6.56 (s, 1H, H-8´´), 6.99 (d, 2H, J=8.0 Hz, H-3´´´,
H-5´´´), 7.48 (d, 2H, J=8.5 Hz, H-2´´´, H-6´´´), 7.83 (s, 2H, H-1, H-2), 8.37 (s, 1H, H-2´´),
12.83 (s, 1H, OH-5´´´), 13.24 (s, 1H, OH-11), 13.98 (s, 1H, OH-6); 13C NMR (125 MHz,
DMSO-d6):17.0 (C-6´), 24.0 (C-14), 24.5 (C-2´´´´), 29.7 (C-2´), 31.4 (C-3´´´´), 31.6 (C-
10), 36.2 (C-8), 45.0 (C-3´), 55.1 (C-OMe-4´´´´), 56.5 (C-OMe-4), 66.7 (C-5´), 67.9 (C-
1´´´´), 68.1 (C-4´), 70.2 (C-7), 75.2 (C-9), 92.7 (C-8´´), 98.3 (C-6´´), 100.3 (C-1´), 105.3
(C-4a´´), 110.5 (C-5a), 110.7 (C-11a), 113.7 (C-3´´´, C-5´´´), 118.9 (C-1), 119.6 (C-3),
119.9 (C-12a), 122.1 (C-3´´), 122.7 (C-1´´´), 130.1 (C-2´´´, C-6´´´), 134.4 (C-10a), 134.6
(C-6a), 135.6 (C-4a), 136.1 (C-2), 154.5 (C-2´´), 154.5 (C-11), 156.1 (C-6), 157.4 (C-8a),
159.2 (C-4´´´), 160.7 (C-4), 161.6 (C-5´´), 164.5 (C-7´´), 170.7 (C-4´´´´), 180.2 (C-4´´),
186.3 (C-12), 186.4 (C-5), 211.7 (C-13).
4.8 Synthesis of dihydrogenistein
Genistein (5) (500 mg), Pd/C 10% (750 mg) and EtOH (50 ml) were placed in a 2-neck
round bottomed flask. The formed suspension was hydrogenated and the reaction was
followed by TLC. After the completion of the reaction, the reaction mixture was filtrated
through a Celite pad and solvent was evaporated in vacuo. The obtained crude product
was purified with MPLC using CH2Cl2:EtOAc (8:2) as an eluent. The evaporation of the
combined fractions gave dihydrogenistein (21) (342 mg, 68%). 1H and 13C NMR (I)
5. CONCLUSIONS
This thesis combines the available literature on the synthesis of isoflavones and their
conjugates, including sulphates, glycosides, protecting groups, various alkyl chains and
carboxylic acids, as well as deuteration and chlorination. This information is valuable
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when planning synthetic routes towards new possible metabolites for biological screening
either originated from mammals or from bacterial broths. The available literature is
divided in chapters according to functionalities and discussed in details. Traditional
synthetic approaches for phenolic derivatives are also included, since the synthesis of
isoflavone O-conjugates arises from those grounds.
The results of this study have provided us with a number of new ways to synthesise
isoflavone derivatives. These include the di-O-sulphates of three major isoflavones,
daidzein (4), genistein (5) and glycitein (6) and di-O-sulphates of their reduced forms,
dihydrodaidzein (20), dihydrogenistein (21) and equol (19). A new efficient microwave
assisted synthetic method for obtaining deuterated isoflavones was developed. Using
CF3COOD under microwave irradiation, daizein-d6 (88), genistein-d4 (122) and glycitein-
d6 (123) were obtained in high yield and isotopic purity. With the above mentioned
sulphation method, the di-O-sulphates of these deuterated isoflavones were obtained in
moderate yield (124, 125, 126). This method is a useful tool when isotopically labelled
isoflavones and their metabolites are required.
One of the most challenging tasks was the synthesis of daidzein-7-O-b-D-glucuronide-4´-
O-sulphate (16). Since the compound is highly polar and sensitive, the reaction steps had
to be optimised carefully. This synthesised compound can be used in the development of
analytical methods to further understand its biological significance and activity as well as
the metabolic circulation of this particular compound in human.
Different protecting groups were investigated during this study. Optimised protection
procedures for introducing Bn and Bz groups selectively at the position 7-O and 4´-O by
direct introduction or by transacylation can be used in the further study of the synthesis of
naturally occurring isoflavones and their metabolites. The use of a non-hydrogen assisted
method (push and pull) for debenzylation discloses the risk of reduction of the double
bond at C-ring. Still, pressure-controlled hydrogenation reactions for debenzylation should
be further studied.
The aromatic chlorination method using neat thionyl chloride was a result of the
unexpected chlorination during synthesis of isoflavone acid chloride. This developed
method can be used to produce 8-chlorogenistein (131), 6,8-dichlorogenistein (108) and
6,8-dichlorobiochanin A (136). The suitability of this chlorination method should be
investigated for other bacterially produced chlorinated compounds owning the
corresponding hydrogen bonded OH group at para position. The results of the chlorination
of genistein (5) and biochanin A (134) with thionyl chloride can be used in the
bromination studies of these compounds with thionyl bromide.
Daizein-4´-O-b-glucoside (78) was synthesised using protecting group chemistry. This
same method can be used in the synthesis of genistein-4´-O-b-glucoside (77). In
connection with, transacylation was noted to be a useful tool in the synthesis of daidzein-
7-O-triacetylglucuronide-4´-O-Bz (150), starting from daidzein-7-O-Bz (97). The
usefulness of transacylation should be considered also with other ester bonded isoflavone
derivatives.
The use of a Boc2NR moiety instead of the phthalimide group for producing alkylamine
chain derivatives of isoflavones should be studied.222 Boc protection can easily be cleaved
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under acidic conditions without any fear of decomposition of the isoflavone sceleton. The
use of hydrazine hydrate for the cleavage of phthalimide group resulted in a reaction at C-
ring forming a pyrazole. This result can be used for producing pyrazoles also from
daidzein (4), genistein (5), glycitein (6) and biochanin A (134) and study the possible
biological activity of these compounds.
The biochanin A daunorubicin conjugate (153) was synthesised and characterised. The
biological activity was tested on MCF7 and Ishikawa cell lines, showing negligible
activity. However, other potential cell lines will be tested in the future. The synthetic
method described here can be exploited for other isoflavones and isoflavonoids to test
their possible activity. One interesting coumpound of these could be equol (19) which has
shown biological activity in human.
As we have now seen, new synthetic approaches towards isoflavone O-conjugates were
developed during this study. These new methods will hopefully take the synthetic research
of isoflavones and their metabolites one step further. It remains to be seen if these
synthesised compounds will be useful in the development of analytical methods and in
biological studies.
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